Pharmaceutical composition for preventing or treating atopic diseases

Porous silica particles loaded with nucleic acid molecules address the inefficiencies of current treatments by delivering siRNA or dsRNA to suppress TSLP, offering a sustained and effective solution for atopic diseases.

JP7580121B2Active Publication Date: 2024-11-11LEMONEX
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2021505844
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-08-01
Filing Date
2019-08-01
Publication Date
2024-11-11
Estimated Expiration
2039-08-01

AI Technical Summary

Technical Problem

Existing treatments for atopic diseases, such as atopic dermatitis, are inadequate in suppressing the immune-inflammatory reactions that cause itching, and current methods for delivering siRNA or dsRNA, like cationic polymers and lipid nanoparticles, face issues with toxicity, instability, and high costs.

Method used

A pharmaceutical composition using porous silica particles loaded with nucleic acid molecules, such as siRNA or dsRNA, that bind complementary to TSLP mRNA, designed to efficiently suppress TSLP expression by sustained release, overcoming the limitations of existing delivery methods.

Benefits of technology

The composition effectively suppresses TSLP expression, providing a high-efficiency preventive or therapeutic effect on atopic diseases like atopic dermatitis, bronchial asthma, and allergic rhinitis, with controlled release and biodegradability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580121000016
    Figure 0007580121000016
  • Figure 0007580121000017
    Figure 0007580121000017
  • Figure 0007580121000018
    Figure 0007580121000018
Patent Text Reader

Abstract

The present invention relates to a composition that can effectively suppress the expression level of TSLP, thereby preventing or treating atopic diseases such as bronchial asthma, allergic rhinitis, atopic dermatitis, allergic dermatitis, or inflammatory skin diseases with excellent efficiency. [Selected Figure] Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition having excellent preventive or therapeutic effects on atopic diseases. [Background technology]

[0002] Atopic dermatitis is an intractable disease accompanied by chronic itching and skin inflammation. The biggest difference between the clinical symptoms of atopic dermatitis and urticaria is due to the difference in the mechanism that induces itching. Generally, the itch of urticaria is mediated by histamine secreted from mast cells and can be treated with antihistamines, but the itch of atopic dermatitis is mediated by various immune inflammatory responses in addition to histamine, so antihistamines alone cannot effectively regulate even the itch symptoms. Therefore, for the effective treatment of atopic diseases, it is very important to cure the itch mediated by immune responses.

[0003] TSLP (thymic stromal lymphopoietin) is secreted in large amounts from keratinocytes, which are skin epithelial cells, due to chronic inflammatory responses in atopic diseases, and is an important factor mediating the progression of chronic atopic dermatitis patients to complex asthma patients. In addition, TSLP secreted from skin epithelial cells activates TRPA-1 positive somatosensory neurons to induce itch. Although the details of all the functions of TSLP are not known, recent research results have shown that the expression of TSLP is pathologically, immunologically, and molecular biologically associated with atopic diseases such as atopic dermatitis and / or asthma, and TSLP is considered to be an important factor in cosmetics, treatment, and pharmacology.

[0004] To suppress the expression of TSLP, antisense nucleic acids can be used as a chemical therapy method, or a method known as interference RNA can be used. Double-stranded RNA (dsRNA) oligonucleotides and siRNA oligonucleotides can also be used.

[0005] Meanwhile, to date, cationic polymers, lipid nanoparticles (LNPs), viruses and various nanomaterials have been developed for the delivery of siRNA. The clinical application of cationic polymers and LNPs requires attention to the toxicity and / or instability of in vivo structures, and viral gene delivery has problems with low packaging capacity as well as mutagenesis. Chemical modification of the siRNA backbone can increase stability and cellular absorption, but still has disadvantages such as high cost, labor-intensive, time-consuming processes, and the administration of large amounts of siRNA to achieve satisfactory effects in target cells. Summary of the Invention [Problem to be solved by the invention]

[0006] An object of the present invention is to provide a composition that highly efficiently suppresses the expression of TSLP and has excellent effects on preventing or treating atopic diseases. [Means for solving the problem]

[0007] 1. A porous silica particle carrying a nucleic acid molecule that binds complementarily to at least a portion of TSLP mRNA; The porous silica particles have an absorbance ratio t of 1 / 2, as shown in the following mathematical formula 1, of 24 or more, in the pharmaceutical composition for preventing or treating an atopic disease. [Formula 1] A t / A0 (In the formula, A0 is the absorbance of the porous silica particles measured by putting 5 ml of a suspension of the porous silica particles at 1 mg / ml into a cylindrical permeable membrane having pores with a diameter of 50 kDa, Outside the permeable membrane, 15 ml of the same solvent as the suspension is placed in contact with the permeable membrane, and the inside and outside of the permeable membrane are horizontally stirred at 60 rpm at 37°C. The pH of the suspension is 7.4; A t is the absorbance of the porous silica particles measured t hours after the measurement of A0.

[0008] 2. A pharmaceutical composition for preventing or treating an atopic disease according to item 1, wherein the porous silica particles are produced by reacting silica particles having pores with a diameter of less than 5 nm with an expanding agent at 120°C to 180°C for 24 to 96 hours to expand the pores with a diameter of less than 5 nm, and calcining the silica particles with expanded pores at a temperature of 400°C or higher for 3 hours or more.

[0009] 3. In the above item 1, the average diameter of the porous silica particles is 150 nm to 1,000 nm, and the BET surface area is 200 m 2 / g~700m 2 / g and the volume per gram is 0.7 ml to 2.2 ml.

[0010] 4. A pharmaceutical composition for preventing or treating an atopic disease according to item 1 above, wherein the nucleic acid molecule is any one of siRNA, dsRNA, PNA or miRNA.

[0011] 5. In the above item 4, the nucleic acid molecule is an siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 1 and an antisense RNA having the sequence of SEQ ID NO: 47, a dsRNA consisting of a strand having the sequence of SEQ ID NO: 24 and a strand complementary thereto, an siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 2 and an antisense RNA having the sequence of SEQ ID NO: 48, a dsRNA consisting of a strand having the sequence of SEQ ID NO: 25 and a strand complementary thereto, an siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 3 and an antisense RNA having the sequence of SEQ ID NO: 49, a dsRNA consisting of a strand having the sequence of SEQ ID NO: 26 and a strand complementary thereto, an siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 4 and an antisense RNA having the sequence of SEQ ID NO: 50, a dsRNA consisting of a strand having the sequence of SEQ ID NO: 27 and a strand complementary thereto, an siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 5 and an antisense RNA having the sequence of SEQ ID NO: 51, a dsRNA consisting of a strand having the sequence of SEQ ID NO: 28 and a strand complementary thereto, an siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 6 and an antisense RNA having the sequence of SEQ ID NO: 52. siRNA consisting of antisense RNA, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:29 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:7 and an antisense RNA consisting of the sequence of SEQ ID NO:53, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:30 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:8 and an antisense RNA consisting of the sequence of SEQ ID NO:54, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:31 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:9 and an antisense RNA consisting of the sequence of SEQ ID NO:55, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:32 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:10 and an antisense RNA consisting of the sequence of SEQ ID NO:56, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:33 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:11 and an antisense RNA consisting of the sequence of SEQ ID NO:57, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:34 and a strand complementary thereto,siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 12 and an antisense RNA consisting of the sequence of SEQ ID NO: 58, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 35 and a strand complementary thereto, an siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 13 and an antisense RNA consisting of the sequence of SEQ ID NO: 59, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 36 and a strand complementary thereto, an siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 14 and an antisense RNA consisting of the sequence of SEQ ID NO: 60, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 37 and a strand complementary thereto, an siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 15 and an antisense RNA consisting of the sequence of SEQ ID NO: 61, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 38 and a strand complementary thereto, an siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 16 and an antisense RNA consisting of the sequence of SEQ ID NO: 62, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 39 and a strand complementary thereto, a sense RNA consisting of the sequence of SEQ ID NO: 17 and an antisense RNA consisting of the sequence of SEQ ID NO: 63 siRNA consisting of a strand having the sequence of SEQ ID NO: 40 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of a sequence of SEQ ID NO: 18 and an antisense RNA consisting of a sequence of SEQ ID NO: 64, dsRNA consisting of a strand having the sequence of SEQ ID NO: 41 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of a sequence of SEQ ID NO: 19 and an antisense RNA consisting of a sequence of SEQ ID NO: 65, dsRNA consisting of a strand having the sequence of SEQ ID NO: 42 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of a sequence of SEQ ID NO: 20 and an antisense RNA consisting of a sequence of SEQ ID NO: 66, dsRNA consisting of a strand having the sequence of SEQ ID NO: 43 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of a sequence of SEQ ID NO: 21 and an antisense RNA consisting of a sequence of SEQ ID NO: 67, dsRNA consisting of a strand having the sequence of SEQ ID NO: 44 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of a sequence of SEQ ID NO: 22 and an antisense RNA consisting of a sequence of SEQ ID NO: 68, dsRNA consisting of a strand having the sequence of SEQ ID NO: 45 and a strand complementary thereto,A pharmaceutical composition for preventing or treating an atopic disease, comprising at least one siRNA or dsRNA selected from the group consisting of: siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 23 and an antisense RNA consisting of the sequence of SEQ ID NO: 69; and dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 46 and a strand complementary thereto.

[0012] 6. A pharmaceutical composition for preventing or treating an atopic disease according to item 5 above, further comprising a UU sequence at the 3' end of the sense RNA and the antisense RNA sequence.

[0013] 7. A pharmaceutical composition for preventing or treating an atopic disease according to item 5 above, further comprising a dTdT sequence at the 3' end of the sense RNA and the antisense RNA sequence.

[0014] 8. A pharmaceutical composition for preventing or treating an atopic disease, wherein the nucleic acid molecule comprises at least one siRNA or dsRNA selected from the group consisting of siRNA consisting of sense RNA having the sequence of SEQ ID NO: 1 and antisense RNA having the sequence of SEQ ID NO: 47, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 24 and a strand complementary thereto, siRNA consisting of sense RNA having the sequence of SEQ ID NO: 14 and antisense RNA having the sequence of SEQ ID NO: 60, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 37 and a strand complementary thereto, siRNA consisting of sense RNA having the sequence of SEQ ID NO: 21 and antisense RNA having the sequence of SEQ ID NO: 67, and dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 44 and a strand complementary thereto.

[0015] 9. A pharmaceutical composition for preventing or treating an atopic disease, wherein the nucleic acid molecule according to item 8 comprises siRNA consisting of sense RNA consisting of the sequence of SEQ ID NO: 1 and antisense RNA consisting of the sequence of SEQ ID NO: 47, or dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 24 and a strand complementary thereto.

[0016] 10. A pharmaceutical composition for preventing or treating an atopic disease according to item 1, wherein the porous silica particles have an outer surface or the inside of the pores that are positively charged at neutral pH.

[0017] 11. A pharmaceutical composition for preventing or treating an atopic disease according to item 1, wherein the porous silica particles have hydrophilic or hydrophobic functional groups.

[0018] 12. A pharmaceutical composition for preventing or treating an atopic disease according to item 1, wherein the atopic disease is at least one selected from the group consisting of bronchial asthma, allergic rhinitis, urticaria, atopic dermatitis, allergic conjunctivitis, allergic dermatitis, allergic contact dermatitis, inflammatory skin diseases, pruritus, and food allergies. Effect of the Invention

[0019] The composition of the present invention can efficiently and sustainably deliver a nucleic acid molecule capable of effectively suppressing the expression of TSLP, thereby suppressing the expression of TSLP with excellent efficiency, thereby exhibiting preventive or therapeutic effects on various atopic diseases caused by overexpression of TSLP. [Brief description of the drawings]

[0020] [Figure 1] FIG. 1 shows the MS analysis of the synthesized SLIGRL peptide. [Diagram 2] FIG. 2 is a micrograph of a porous silica particle according to one embodiment of the present invention. [Diagram 3] FIG. 3 is a micrograph of a porous silica particle according to one embodiment of the present invention. [Figure 4] FIG. 4 is a micrograph of small pore particles in a process for producing porous silica particles according to one embodiment of the present invention. [Diagram 5] FIG. 5 is a micrograph of a small pore particle according to one embodiment of the present invention. [Figure 6]6 is a micrograph of the pore diameter of porous silica particles according to one embodiment of the present invention. DDV (Degradable Delivery Vehicle) is an example particle, the number in parentheses means the particle diameter, and the number in subscript means the pore diameter. For example, DDV (200) 10 means an example particle with a particle diameter of 200 nm and a pore diameter of 10 nm. [Figure 7] FIG. 7 is a micrograph showing the biodegradability of the porous silica particles according to one embodiment of the present invention. [Figure 8] FIG. 8 shows an example of a cylindrical tube with a permeable membrane. [Figure 9] FIG. 9 shows the result of the decrease in absorbance over time for porous silica particles according to one embodiment of the present invention. [Figure 10] FIG. 10 shows the result of the decrease in absorbance over time for the porous silica particles according to one embodiment of the present invention, classified by particle size. [Figure 11] FIG. 11 shows the result of the decrease in absorbance over time for each pore diameter of the porous silica particles according to one embodiment of the present invention. [Figure 12] FIG. 12 shows the result of the decrease in absorbance of the porous silica particles according to one embodiment of the present invention over time depending on the pH of the environment. [Figure 13] FIG. 13 shows the result of the decrease in absorbance over time for porous silica particles according to one embodiment of the present invention. [Figure 14] FIG. 14 shows an example of a tube confirming the release of siRNA or dsRNA. [Figure 15] FIG. 15 shows the degree of release over time of siRNA loaded on porous silica particles according to one embodiment of the present invention. [Figure 16] FIG. 16 shows the morphological characteristics of siRNA-loaded DDV in HaCaT cells. [Figure 17] FIG. 17 shows the morphological characteristics of siRNA-loaded DDV in HeLa cells. [Figure 18]FIG. 18 shows that TSLP expression is induced in HaCaT cells upon treatment with SLIGRL. [Figure 19] Figure 19 shows the results of treating HaCaT cells with LEM-siTSLP#1, LEM-siTSLP#14, or LEM-siTSLP#21, inducing TSLP by treatment with SLIGRL 12 hours before harvesting, and then confirming the expression level of TSLP mRNA using RT-PCR. [Figure 20] FIG. 20 shows the results of comparing the expression levels of TSLP mRNA when HaCaT cells were treated with LEM-siTSLP and LNPs carrying siTSLP. [Figure 21] FIG. 21 shows a fluorescent image of the skin excised from a mouse after injection of LEM-siTSLP(mouse) into the skin. [Figure 22] FIG. 22 shows a fluorescent image obtained by injecting FITC-conjugated siTSLP (mouse) not supported on DegradaBALL into mouse skin and then excising the skin. [Diagram 23] FIG. 23 shows fluorescent images of mouse skin that was injected with LEM-siTSLP(mouse) and then the skin was excised, confirming the delivery effect and distribution change of LEM-siTSLP(mouse). [Figure 24] FIG. 24 shows the results of scratching behavior analysis of mice injected with LEM-siTSLP(mouse). [Diagram 25] FIG. 25 shows the results of scratching behavior analysis of mice injected with LEM-siTSLP(mouse). [Figure 26] FIG. 26 shows the experimental results of observing cell viability after treating cells with DegradaBALL. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] In the detailed description of the present invention, specific meanings of terms are defined, but these are merely accepted as meanings understood by those of ordinary skill in the art, and are not intended to be limited to the specific meanings defined below.

[0022] "siRNA" refers to a nucleic acid molecule capable of mediating RNA interference or gene silencing. siRNA can suppress the expression of a target gene, and is therefore provided as an efficient method for gene knockdown or gene therapy. An siRNA molecule can have a double-stranded structure in which a sense strand (a sequence corresponding to the mRNA sequence of a target gene) and an antisense strand (a sequence complementary to the mRNA sequence of a target gene) are positioned opposite each other. An siRNA molecule can also have a single-stranded structure having self-complementary sense and antisense strands. siRNA is not limited to RNAs in which the double-stranded RNA portion that pairs with the RNAs is completely paired, and can include portions that are not paired due to mismatches (corresponding bases are not complementary), bulges (there is no corresponding base in one strand), etc. The terminal structure of an siRNA can be either blunt or cohesive, as long as it can suppress the expression of a target gene by the RNAi (RNA interference) effect. The sticky end structure can be either a 3'-end overhang structure or a 5'-end overhang structure. The siRNA molecule can also have a form in which a short nucleotide sequence (e.g., about 5-15 nt) is inserted between the self-complementary sense and antisense strands. In this case, the siRNA molecule formed by expression of the nucleotide sequence will form a hairpin structure by intramolecular hybridization, and will form a stem-and-loop structure as a whole. This stem-and-loop structure is processed in vitro or in vivo to generate an active siRNA molecule that can mediate RNAi.

[0023] "dsRNA" is a precursor molecule of siRNA, which associates with the RISC complex containing the DICER enzyme (Ribonuclease III) in the target cell and is cleaved into siRNA, during which RNAi occurs. dsRNA has a sequence several nucleotides longer than siRNA, and can have a double-stranded structure in which the sense strand (a sequence corresponding to the mRNA sequence of the target gene) and the antisense strand (a sequence complementary to the mRNA sequence of the target gene) are positioned opposite each other.

[0024] "PNA" is a synthetic polymer with a structure similar to DNA or RNA, but unlike DNA or RNA, it is designed to be uncharged and has strong binding power. While DNA and RNA have a deoxyribose or ribose sugar backbone, respectively, PNA's backbone has a structure in which repeating N-(2-aminoethyl)-glycine units are linked by peptide bonds. Purine and pyrimidine bases are linked to the backbone by methylene (-CH2-) and carbonyl groups (-C=O-), and like peptides, it has an N-terminus and a C-terminus at both ends.

[0025] By "nucleic acid" it is meant to include any PNA, DNA or RNA, e.g., chromosomal, mitochondrial, viral and / or bacterial nucleic acid present in a tissue sample, including any one or both strands of a double-stranded nucleic acid molecule, including any fragment or portion of an intact nucleic acid molecule.

[0026] By "gene" is meant any nucleic acid sequence or portion thereof that has a functional role in coding or transcription of a protein or in regulating the expression of other genes. A gene can consist of all the nucleic acid that codes for a functional protein or only a portion of the nucleic acid that codes for or expresses a protein. A nucleic acid sequence can contain genetic abnormalities within exons, introns, start or end regions, promoter sequences, other regulatory sequences, or unique sequences adjacent to the gene.

[0027] The term "gene expression" generally refers to the cellular process by which biologically active polypeptides are produced from DNA sequences and exhibit biological activity in cells. In this sense, gene expression not only includes the processes of transcription and decoding, but also includes post-transcriptional and post-decoding processes that can affect the biological activity of genes or gene products. The processes include, but are not limited to, RNA synthesis, processing and transport, as well as polypeptide synthesis, transport, and post-decoding modifications of polypeptides. The term "gene expression" in the case of genes that do not code for protein products, such as siRNA genes, refers to the process by which precursor siRNAs are produced from the genes. Typically, the process is referred to as transcription, even though the transcripts of siRNA genes are not decoded to produce proteins, unlike the transcription induced by RNA polymerase II for protein-coding genes. Nevertheless, the production of mature siRNAs from siRNA genes is encompassed by the term "gene expression" as that term is used herein.

[0028] The term "target gene" refers to the gene that is targeted for modulation using the subject methods and compositions disclosed herein.Thus, a target gene includes the nucleic acid sequence whose expression level is down-regulated by siRNA at the level of mRNA or polypeptide.Similarly, the term "target RNA" or "target mRNA" refers to the transcript of the target gene that siRNA binds to induce the regulation of the expression of the target gene.

[0029] The term "transcription" refers to the cellular process involving the interaction of a gene with RNA polymerase that leads to the expression of the structural information present in the gene's coding sequence into RNA.

[0030] The term "down-regulation" refers to a significant decrease in the amount of mRNA or protein expression of a specific gene, either through intracellular gene transcription or translation, in activated cells compared to normal tissue cells.

[0031] "Treatment" refers to access to obtain beneficial or desired clinical results. For purposes of the present invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in the extent of disease, stabilization of the disease state (i.e., not worsening), delay or slowing of disease progression, improvement or palliation and relief of the disease state (partial or complete), detectable or undetectable. "Treatment" can also mean prolonging survival compared to the expected survival in the absence of treatment. Treatment refers to both therapeutic treatment and prophylactic or preventative measures. The treatment includes treatment required in disorders already occurring, as well as disorders that are prevented.

[0032] "Prevention" refers to any action that inhibits or delays the onset of the associated disease. It will be apparent to those skilled in the art that the compositions of the present application can prevent the associated disease when administered before the initial symptoms or manifestations.

[0033] The present invention will be described in detail below.

[0034] The present invention provides a composition for inhibiting thymic stromal lymphopoietin (TSLP) gene expression, comprising porous silica particles carrying a nucleic acid molecule that binds complementarily to at least a portion of a transcript of the TSLP gene. The porous silica particles are made of silica (SiO2) and have a nano-sized particle size.

[0035] The porous silica nanoparticles of the present invention are porous particles having nano-sized pores and can carry on their surface (external surface) and / or inside the pores a nucleic acid molecule that binds complementarily to at least a portion of TSLP mRNA.

[0036] The TSLP mRNA of the present invention may be mRNA derived from the same species as the intended target species, for example, but is not limited to, the sequence of SEQ ID NO: 149 in the case of humans. For example, the TSLP mRNA of the present invention may be human TSLP mRNA, mouse TSLP mRNA, monkey TSLP mRNA, or rabbit TSLP mRNA, and preferably, human TSLP mRNA, but is not limited to these.

[0037] The nucleic acid molecule of the present invention can be designed to vary depending on the TSLP mRNA sequence. For example, the nucleic acid molecule of the present invention may be designed to be capable of complementary binding to the human TSLP mRNA sequence, but is not limited thereto.

[0038] The porous silica particles of the present invention are biodegradable particles, and when administered to the body carrying a nucleic acid molecule that binds complementarily to at least a portion of TSLP mRNA, they can be biodegraded in the body to release the nucleic acid molecule that binds complementarily to at least a portion of TSLP mRNA. That is, the porous silica particles of the present invention can be gradually degraded in the body to gradually release the nucleic acid molecule that binds complementarily to at least a portion of the carried TSLP mRNA. For example, t, at which the absorbance ratio in the following formula 1 becomes 1 / 2, is 24 or more.

[0039] [Formula 1] A t / A0 (In the formula, A0 is the absorbance of the porous silica particles measured by putting 5 ml of a suspension of 1 mg / ml of the porous silica particles into a cylindrical permeable membrane having pores with a diameter of 50 kDa, Outside the permeable membrane, 15 ml of the same solvent as the suspension is placed in contact with the permeable membrane, and the inside and outside of the permeable membrane are horizontally stirred at 60 rpm at 37°C. The pH of the suspension is 7.4; A t is the absorbance of the porous silica particles measured t hours after the measurement of A0.

[0040] The above formula 1 indicates the rate at which the porous silica particles are decomposed in an environment similar to that in the body.

[0041] The absorbances A0 and A t For example, as shown in FIG. 8, the measurement can be performed by placing porous silica particles and a suspension in a cylindrical permeable membrane and placing the same suspension on the outside of the permeable membrane.

[0042] The porous silica particles of the present invention are biodegradable and can be gradually decomposed in suspension.The diameter of 50kDa corresponds to about 5nm, and the biodegraded porous silica particles can pass through a permeable membrane with a diameter of 50kDa.The cylindrical permeable membrane is under horizontal stirring at 60rpm, so that the suspension can be mixed uniformly, and the decomposed porous silica particles can be released to the outside of the permeable membrane.

[0043] The absorbance in the above formula 1 may be measured, for example, in an environment where the suspension outside the permeable membrane is replaced with a new suspension. The suspension may be replaced continuously or at regular intervals. The regular intervals may be regular or irregular. For example, the suspension may be replaced every hour, every 2 hours, every 3 hours, every 6 hours, every 12 hours, every 24 hours, every 2 days, every 3 days, every 4 days, every 7 days, etc. within a range of 1 hour to 1 week, but is not limited thereto.

[0044] The "absorbance ratio becomes 1 / 2" means that the absorbance after time t becomes half of the initial absorbance, which means that about half of the porous silica particles have been decomposed.

[0045] The suspension may be a buffer solution, specifically, one or more selected from the group consisting of PBS (phosphate buffered saline) and SBF (simulated body fluid), more specifically, PBS.

[0046] The value t at which the absorbance ratio in the formula 1 of the present invention becomes 1 / 2 is 24 or more, and may be, for example, 24 to 120, and may be, for example, 24 to 96, 24 to 72, 30 to 70, 40 to 70, 50 to 65, etc., within the above range, but is not limited thereto.

[0047] In the porous silica particles of the present invention, t, at which the absorbance ratio in the above formula 1 becomes 1 / 5, may be, for example, 70 to 140, and may be, for example, 80 to 140, 80 to 120, 80 to 110, 70 to 140, 70 to 120, 70 to 110, etc. within the above range, but is not limited thereto.

[0048] In the porous silica particles of the present invention, t, at which the absorbance ratio in the above formula 1 becomes 1 / 20, may be, for example, 130 to 220, and may be, for example, within the above range, 130 to 200, 140 to 200, 140 to 180, 150 to 180, etc., but is not limited to these.

[0049] The porous silica particles of the present invention may have a t at which the measured absorbance is 0.01 or less, for example, 250 or more, 300 or more, 350 or more, 400 or more, 500 or more, 1,000 or more, and the upper limit may be 2,000, but is not limited to these.

[0050] In the porous silica particles of the present invention, the absorbance ratio in Equation 1 and t have a high degree of correlation, for example, the Pearson correlation coefficient may be 0.8 or more, for example, 0.9 or more, or 0.95 or more.

[0051] The t in the above formula 1 means the rate at which the porous silica particles are decomposed in an environment similar to that in the body, which can be adjusted by, for example, adjusting the surface area, particle size, pore diameter, surface and / or pore interior substituents, surface compactness, etc. of the porous silica particles.

[0052] For example, the surface area of ​​the particle can be increased to decrease t, or the surface area can be decreased to increase t. The surface area can be adjusted by adjusting the diameter of the particle and the diameter of the pores. In addition, the direct exposure of the porous silica particle to the environment (solvent, etc.) can be reduced by positioning a substituent on the surface and / or inside the pores, thereby increasing t. In addition, the affinity between the porous silica particle and the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA can be increased by carrying the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA on the porous silica particle, thereby reducing the direct exposure of the porous silica particle to the environment, thereby increasing t. In addition, the surface can be made more dense during the production of the particles to increase t. Various examples of how t in Formula 1 can be adjusted have been given above, but the present invention is not limited thereto.

[0053] The porous silica particles of the present invention may be, for example, spherical particles, but are not limited thereto.

[0054] The porous silica particles of the present invention may have an average particle size of, for example, 150 nm to 1,000 nm, and may be, for example, within the above-mentioned range, 150 nm to 800 nm, 150 nm to 500 nm, 150 nm to 400 nm, 150 nm to 300 nm, or 150 nm to 200 nm, but is not limited to these.

[0055] The porous silica particles of the present invention may have an average pore diameter of, for example, 1 nm to 100 nm, and may be, for example, within the above range, 5 nm to 100 nm, 7 nm to 100 nm, 7 nm to 50 nm, 10 nm to 50 nm, 10 nm to 30 nm, or 7 nm to 30 nm, but are not limited thereto. With such a large diameter, a large amount of nucleic acid molecules that bind complementarily to at least a portion of TSLP mRNA can be supported, and it is also possible to support nucleic acid molecules that bind complementarily to at least a portion of large-sized TSLP mRNA.

[0056] The porous silica particles of the present invention have a BET surface area of, for example, 200 m 2 / g~700m 2 For example, the range may be 200 m / g. 2 / g~700m 2 / g, 200m 2 / g~650m 2 / g, 250m 2 / g~650m 2 / g, 300m 2 / g~700m 2 / g, 300m 2 / g~650m 2 / g, 300m 2 / g~600m 2 / g, 300m 2 / g~550m 2 / g, 300m 2 / g~500m 2 / g, 300m 2 / g~450m 2 / g, but is not limited thereto.

[0057] The porous silica nanoparticles of the present invention may have a volume per gram of, for example, 0.7 ml to 2.2 ml. For example, within the above range, the volume may be 0.7 ml to 2.0 ml, 0.8 ml to 2.2 ml, 0.8 ml to 2.0 ml, 0.9 ml to 2.0 ml, 1.0 ml to 2.0 ml, etc., but is not limited thereto. If the volume per gram is too small, the decomposition rate may be too fast, and if it is too large, it may be difficult to manufacture or may not have a perfect shape.

[0058] The porous silica particles of the present invention may have hydrophilic and / or hydrophobic substituents on the outer surface and / or inside the pores. For example, only hydrophilic or only hydrophobic substituents may be present on both the surface and inside the pores, or only hydrophilic or only hydrophobic substituents may be present on either the surface or inside the pores. Also, hydrophilic or hydrophobic substituents may be present on the surface and inside the pores, respectively, and vice versa.

[0059] The release of the nucleic acid molecule that is complementary to at least a part of the TSLP mRNA supported on the porous silica particles of the present invention is mainly caused by the decomposition of the nanoparticles. Therefore, by adjusting the substituent, the interaction of the porous silica particles with the release environment of the nucleic acid molecule that is complementary to at least a part of the TSLP mRNA can be adjusted, and the decomposition rate of the nanoparticles themselves can be adjusted to adjust the release rate of the nucleic acid molecule that is complementary to at least a part of the TSLP mRNA. In addition, the nucleic acid molecule that is complementary to at least a part of the TSLP mRNA can be released by diffusion from the nanoparticles, but by adjusting the substituent, the binding force of the nucleic acid molecule that is complementary to at least a part of the TSLP mRNA to the nanoparticles can be adjusted, and the release of the nucleic acid molecule that is complementary to at least a part of the TSLP mRNA can be adjusted.

[0060] In addition, in order to strengthen the binding strength with nucleic acid molecules or substances that complementarily bind to at least a portion of the poorly soluble (hydrophobic) TSLP mRNA, it is also possible to treat the particles so that hydrophobic substituents are present inside the pores, and hydrophilic substituents are present on the surface of the particles for ease of use and formulation.

[0061] Examples of hydrophilic substituents include hydroxyl, carboxyl, amino, carbonyl, sulfhydryl, phosphate, thiol, ammonium, ester, imide, thioimide, keto, ether, indene, sulfonyl, polyethylene glycol, etc. Examples of hydrophobic substituents include substituted or unsubstituted C1-C 30 Alkyl groups, substituted or unsubstituted C3-C 30 Cycloalkyl groups, substituted or unsubstituted C6-C 30 aryl groups, substituted or unsubstituted C2-C 30 Heteroaryl groups, halogen groups, C1-C 30 and halogen-containing groups.

[0062] In addition, the porous silica particles of the present invention may have an external surface and / or an inside of a pore positively charged, negatively charged, and / or uncharged. For example, both the surface and the inside of a pore may be positively charged or negatively charged, or only one of the surface or the inside of a pore may be positively charged or negatively charged. In addition, the surface may be positively charged and the inside of a pore may be negatively charged, or vice versa, and the same applies to the case of uncharged.

[0063] The charge may be effected, for example, by the presence of non-ionic, cationic or anionic substituents.

[0064] The cationic substituent may be, for example, an amino group or other nitrogen-containing group as a basic group, and specifically may be at least one functional group selected from the group consisting of an amino group, an aminoalkyl group, an alkylamino group, a heterocyclic aromatic compound group containing a nitrogen atom, a cyan group, and a guanidine group, but is not limited thereto.

[0065] The anionic substituent may be, for example, an acidic group such as a carboxy group (-COOH), a sulfonic acid group (-SO3H), or a thiol group (-SH), but is not limited thereto.

[0066] Similarly, the charge can be used to adjust the interaction of the porous silica particles with the release environment of the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA by adjusting the substituent, and the decomposition rate of the nanoparticles themselves can be adjusted to adjust the release rate of the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA. Also, the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA can be released by diffusion from the nanoparticles, but the binding force of the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA to the nanoparticles can be adjusted by adjusting the substituent, and the release of the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA can be adjusted.

[0067] In addition, the porous silica particles of the present invention may have on their surface and / or inside their pores, in addition to the above, substituents for carrying a nucleic acid molecule that binds complementarily to at least a portion of TSLP mRNA, transferring a nucleic acid molecule that binds complementarily to at least a portion of TSLP mRNA to a target cell, carrying substances for other purposes, or binding other additional substituents, and may further include an antibody, ligand, cell-permeable peptide, aptamer, etc. bound thereto.

[0068] The aforementioned surface and / or internal pore substituents, charges, binding substances, etc. can be added, for example, by surface modification.

[0069] The surface modification can be carried out, for example, by reacting a compound having a substituent to be introduced with the particles, and the compound may be, for example, an alkoxysilane having an alkoxy group of C1 to C10, but is not limited thereto. The alkoxysilane has one or more alkoxy groups, for example, 1 to 3 alkoxy groups, and the substituent to be introduced may be present at a site not bonded to the alkoxy group, or a substituent substituted therewith may be present.

[0070] The porous silica particles of the present invention may be produced, for example, through a process of producing particles with small pores and a process of expanding the pores, and may be produced, if necessary, through a process of calcination, surface modification, etc. When both the calcination and surface modification processes are performed, the surface may be modified after calcination.

[0071] The small pore particles may be, for example, particles with an average pore diameter of 1 nm to 5 nm.

[0072] The small pore particles can be obtained by stirring and homogenizing a surfactant and a silica precursor in a solvent.

[0073] The solvent may be water and / or an organic solvent. Examples of organic solvents include ethers (especially cyclic ethers) such as 1,4-dioxane; halogenated hydrocarbons such as chloroform, methylene chloride, carbon tetrachloride, 1,2-dichloroethane, dichloroethylene, trichloroethylene, perchloroethylene, dichloropropane, amyl chloride, and 1,2-dibromoethane; ketones such as acetone, methyl isobutyl ketone, γ-butyrolactone, 1,3-dimethyl-imidazolidinone, methyl ethyl ketone, cyclohexanone, cyclopentanone, and 4-hydroxy-4-methyl-2-pentanone; carbon-based aromatics such as benzene, toluene, xylene, and tetramethylbenzene; alkylamides such as N,N-dimethylformamide, N,N-dibutylformamide, N,N-dimethylacetamide, and N-methylpyrrolidone; alcohols such as methanol, ethanol, propanol, and butanol; ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, ethylene glycol monobutyl ether, and diethylene glycol monoethyl ether. Glycol ethers (cellosolves) such as ethylene glycol monomethyl ether, diethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, dipropylene glycol diethyl ether, and triethylene glycol monoethyl ether; and other dimethylacetamide (DMAc), N,N-diethylacetamide, dimethylformamide (DMF), diethylformamide (DEF), N,N-dimethylacetamide (DMAc), N-methylpyrrolidone (NMP), N-ethylpyrrolidone (NEP), 1,3-dimethyl-2-imidazolidinone, N,N-dimethylmethoxyacetamide, dimethylsulfoxide, pyridine, dimethylsulfone, hexamethylphosphoramide, tetramethylurea, N-methylcaprolactam, tetrahydrofuran, m-dioxane, p-dioxane, and 1,2-dimethoxyethane can be used. Specifically, alcohol, more specifically, methanol can be used, but the use of these is not limited thereto.

[0074] In the above solvent, the ratio of water to organic solvent when used in a mixed solvent is, for example, 1:0.7 to 1.5 by volume, such as 1:0.8 to 1.3 by volume, but is not limited thereto.

[0075] The surfactant may be, for example, CTAB (cetyltrimethylammonium bromide), TMABr (hexadecyltrimethylammonium bromide), TMPrCl (hexadecyltrimethylpyridinium chloride), TMACl (tetramethylammonium chloride), or the like, and specifically, CTAB can be used.

[0076] The surfactant can be added in an amount of, for example, 1 g to 10 g per 1 liter of solvent, for example, 1 g to 8 g, 2 g to 8 g, 3 g to 8 g, etc., within the above range, but is not limited thereto.

[0077] The silica precursor may be added after adding a surfactant to the solvent and stirring it. The silica precursor may be, for example, but is not limited to, TMOS (tetramethyl orthosilicate).

[0078] The stirring can be performed for, but is not limited to, 10 to 30 minutes.

[0079] The silica precursor can be added in an amount of, for example, 0.5 ml to 5 ml per liter of solvent, for example, 0.5 ml to 4 ml, 0.5 ml to 3 ml, 0.5 ml to 2 ml, 1 ml to 2 ml, etc., within the above range, but is not limited to these.

[0080] If desired, sodium hydroxide can be further used as a catalyst, which can be added with stirring after the addition of the surfactant to the solvent and before the addition of the silica precursor.

[0081] The amount of the sodium hydroxide may be, for example, 0.5 ml to 8 ml per liter of solvent based on a 1 M aqueous sodium hydroxide solution, for example, within the above range of 0.5 ml to 5 ml, 0.5 ml to 4 ml, 1 ml to 4 ml, 1 ml to 3 ml, 2 ml to 3 ml, etc., but is not limited to these.

[0082] After the silica precursor is added, the solution can be stirred to react. Stirring can be performed for, for example, 2 hours to 15 hours, and may be, for example, within the above range, 3 hours to 15 hours, 4 hours to 15 hours, 4 hours to 13 hours, 5 hours to 12 hours, 6 hours to 12 hours, 6 hours to 10 hours, etc., but is not limited thereto. If the stirring time (reaction time) is too short, crystal nucleation may be insufficient.

[0083] After the stirring, the solution can be aged. The aging can be performed for, for example, 8 hours to 24 hours, and may be, for example, within the above range, 8 hours to 20 hours, 8 hours to 18 hours, 8 hours to 16 hours, 8 hours to 14 hours, 10 hours to 16 hours, 10 hours to 14 hours, etc., but is not limited thereto.

[0084] The reaction product can then be washed and dried to obtain porous silica particles. If necessary, washing can be preceded by separation of unreacted materials.

[0085] The separation of the unreacted substances can be carried out, for example, by separating the supernatant by centrifugation. The centrifugation can be carried out, for example, at 6,000 to 10,000 rpm. The time period can be, for example, 3 to 60 minutes, and may be, for example, 3 to 30 minutes, 3 to 30 minutes, 5 to 30 minutes, etc., within the above range, but is not limited thereto.

[0086] The washing can be performed with water and / or an organic solvent, and specifically, since different solvents can dissolve different substances, water and an organic solvent can be used alternately once or several times, or water or an organic solvent can be used alone once or several times. The number of times can be, for example, 2 to 10 times, for example, 3 to 10 times, 4 to 8 times, 4 to 6 times, etc.

[0087] Examples of the organic solvent include ethers (particularly cyclic ethers) such as 1,4-dioxane; halogenated hydrocarbons such as chloroform, methylene chloride, carbon tetrachloride, 1,2-dichloroethane, dichloroethylene, trichloroethylene, perchloroethylene, dichloropropane, amyl chloride, and 1,2-dibromoethane; ketones such as acetone, methyl isobutyl ketone, γ-butyrolactone, 1,3-dimethyl-imidazolidinone, methyl ethyl ketone, cyclohexanone, cyclopentanone, and 4-hydroxy-4-methyl-2-pentanone; carbon-based aromatics such as benzene, toluene, xylene, and tetramethylbenzene; alkylamides such as N,N-dimethylformamide, N,N-dibutylformamide, N,N-dimethylacetamide, and N-methylpyrrolidone; alcohols such as methanol, ethanol, propanol, and butanol; ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, ethylene glycol monobutyl ether, diethylene glycol monoethyl ether, and the like. glycol ethers (cellosolves) such as propylene glycol monomethyl ether, diethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, dipropylene glycol diethyl ether, and triethylene glycol monoethyl ether; and other dimethylacetamide (DMAc), N,N-diethylacetamide, dimethylformamide (DMF), diethylformamide (DEF), N,N-dimethylacetamide (DMAc), N-methylpyrrolidone (NMP), N-ethylpyrrolidone (NEP), 1,3-dimethyl-2-imidazolidinone, N,N-dimethylmethoxyacetamide, dimethylsulfoxide, pyridine, dimethylsulfone, hexamethylphosphoramide, tetramethylurea, N-methylcaprolactam, tetrahydrofuran, m-dioxane, p-dioxane, and 1,2-dimethoxyethane, specifically, alcohol, more specifically, ethanol, can be used, but the use is not limited thereto.

[0088] The washing can be performed under centrifugation, for example, at 6,000 to 10,000 rpm, for a period of time of, for example, 3 to 60 minutes, and may be within the above range, for example, 3 to 30 minutes, 3 to 30 minutes, 5 to 30 minutes, etc., but is not limited thereto.

[0089] The washing can also be performed by filtering the particles through a filter without centrifuging. The filter may have pores with a diameter equal to or smaller than that of the porous silica particles. When the reaction solution is filtered through such a filter, only the particles remain on the filter, and the filter can be washed by pouring water and / or an organic solvent onto the filter.

[0090] In the washing, water and an organic solvent may be used alternately once or several times, or water or an organic solvent may be used alone once or several times. The number of times may be, for example, 2 to 10 times, for example, 3 to 10 times, 4 to 8 times, or 4 to 6 times.

[0091] The drying can be carried out, for example, at 20° C. to 100° C., but is not limited thereto, and can also be carried out in a vacuum state.

[0092] Thereafter, the pores of the porous silica particles obtained above are expanded, which can be achieved by using a pore expanding agent.

[0093] Examples of the pore expander include trimethylbenzene, triethylbenzene, tripropylbenzene, tributylbenzene, tripentylbenzene, trihexylbenzene, toluene, and benzene. Specifically, trimethylbenzene can be used, but is not limited thereto.

[0094] The pore expanding agent may be, for example, N,N-dimethylhexadecylamine (DMHA), but is not limited thereto.

[0095] The pores can be expanded, for example, by mixing the porous silica particles in a solvent with a pore expanding agent and heating the mixture to cause a reaction.

[0096] The solvent may be, for example, water and / or an organic solvent. Examples of the organic solvent include, but are not limited to, ethers (particularly cyclic ethers) such as 1,4-dioxane; halogenated hydrocarbons such as chloroform, methylene chloride, carbon tetrachloride, 1,2-dichloroethane, dichloroethylene, trichloroethylene, perchloroethylene, dichloropropane, amyl chloride, and 1,2-dibromoethane; ketones such as acetone, methyl isobutyl ketone, and cyclohexanone; carbon-based aromatics such as benzene, toluene, and xylene; alkylamides such as N,N-dimethylformamide, N,N-dibutylformamide, N,N-dimethylacetamide, and N-methylpyrrolidone; and alcohols such as methanol, ethanol, propanol, and butanol. Specifically, alcohol, more specifically, ethanol, can be used.

[0097] The porous silica particles can be added in an amount of, for example, 10 g to 200 g per 1 liter of solvent, for example, within the above range of 10 g to 150 g, 10 g to 100 g, 30 g to 100 g, 40 g to 100 g, 50 g to 100 g, 50 g to 80 g, 60 g to 80 g, etc., but is not limited to these amounts.

[0098] The porous silica particles may be uniformly dispersed in a solvent, for example, by adding the porous silica particles to a solvent and dispersing them ultrasonically. When a mixed solvent is used, the porous silica particles may be dispersed in a first solvent, and then a second solvent may be added thereto.

[0099] The pore expansion agent can be added in an amount of, for example, 10 to 200 parts by volume relative to 100 parts by volume of the solvent, or within the above range, 10 to 150 parts by volume, 10 to 100 parts by volume, 10 to 80 parts by volume, 30 to 80 parts by volume, 30 to 70 parts by volume, etc., but is not limited to these amounts.

[0100] The reaction can be carried out at, for example, 120° C. to 190° C. For example, the reaction can be carried out at temperatures within the above range, such as 120° C. to 190° C., 120° C. to 180° C., 120° C. to 170° C., 130° C. to 170° C., 130° C. to 160° C., 130° C. to 150° C., or 130° C. to 140° C., but is not limited thereto.

[0101] The reaction can be carried out for, for example, 6 to 96 hours. For example, within the above range, the time may be 30 hours to 96 hours, 30 hours to 96 hours, 30 hours to 80 hours, 30 hours to 72 hours, 24 hours to 80 hours, 24 hours to 72 hours, 36 hours to 96 hours, 36 hours to 80 hours, 36 hours to 72 hours, 36 hours to 66 hours, 36 hours to 60 hours, 48 ​​hours to 96 hours, 48 ​​hours to 88 hours, 48 ​​hours to 80 hours, 48 ​​hours to 72 hours, 6 hours to 96 hours, 7 hours to 96 hours, 8 hours to 80 hours, 9 hours to 72 hours, 9 hours to 80 hours, 6 hours to 72 hours, 9 hours to 96 hours, 10 hours to 80 hours, 10 hours to 72 hours, 12 hours to 66 hours, 13 hours to 60 hours, 14 hours to 96 hours, 15 hours to 88 hours, 16 hours to 80 hours, 17 hours to 72 hours, and the like, but is not limited to these.

[0102] The time and temperature can be adjusted within the above-mentioned ranges so that the reaction is carried out sufficiently without being excessive. For example, the reaction time can be increased when the reaction temperature is low, and the reaction time can be decreased when the reaction temperature is high. If the reaction is not sufficient, the pores may not expand sufficiently, and if the reaction proceeds too far, the particles may collapse due to excessive pore expansion.

[0103] The reaction can be carried out, for example, by increasing the temperature stepwise. Specifically, the reaction can be carried out by increasing the temperature stepwise from room temperature to the above temperature at a rate of 0.5° C. / min to 15° C. / min, and may be, for example, within the above range, 1° C. / min to 15° C. / min, 3° C. / min to 15° C. / min, 3° C. / min to 12° C. / min, 3° C. / min to 10° C. / min, etc., but is not limited thereto.

[0104] The reaction can be carried out under stirring. For example, the reaction can be carried out at a stirring speed of 100 rpm or more, specifically, at a speed of 100 rpm to 1,000 rpm, but is not limited thereto.

[0105] After the reaction, the reaction solution can be gradually cooled, for example, by stepwise decreasing the temperature. Specifically, the temperature can be decreased stepwise from the above temperature to room temperature at a rate of 0.5°C / min to 20°C / min, and may be, for example, within the above range, 1°C / min to 20°C / min, 3°C / min to 20°C / min, 3°C / min to 12°C / min, 3°C / min to 10°C / min, etc., but is not limited thereto.

[0106] After cooling, the reaction product can be washed and dried to obtain porous silica particles with expanded pores. If necessary, unreacted materials can be separated prior to washing.

[0107] The separation of the unreacted substances can be carried out, for example, by separating the supernatant by centrifugation. The centrifugation can be carried out, for example, at 6,000 to 10,000 rpm. The time period can be, for example, 3 to 60 minutes, and may be, for example, 3 to 30 minutes, 3 to 30 minutes, 5 to 30 minutes, etc., within the above range, but is not limited thereto.

[0108] The washing can be performed with water and / or an organic solvent. Specifically, since different solvents can dissolve different substances, water and an organic solvent may be used alternately once or several times, or water or an organic solvent may be used alone once or several times. The number of times may be, for example, 2 or more and 10 or less, for example, 3, 4, 5, 6, 7, 8, etc.

[0109] Examples of the organic solvent that can be used include ethers (particularly cyclic ethers) such as 1,4-dioxane; halogenated hydrocarbons such as chloroform, methylene chloride, carbon tetrachloride, 1,2-dichloroethane, dichloroethylene, trichloroethylene, perchloroethylene, dichloropropane, amyl chloride, and 1,2-dibromoethane; ketones such as acetone, methyl isobutyl ketone, and cyclohexanone; carbon-based aromatics such as benzene, toluene, and xylene; alkylamides such as N,N-dimethylformamide, N,N-dibutylformamide, N,N-dimethylacetamide, and N-methylpyrrolidone; and alcohols such as methanol, ethanol, propanol, and butanol. Specifically, alcohol, more specifically, ethanol, can be used, but the organic solvent is not limited to these.

[0110] The washing can be performed under centrifugation, for example, at 6,000 to 10,000 rpm, for a period of time of, for example, 3 to 60 minutes, and may be within the above range, for example, 3 to 30 minutes, 3 to 30 minutes, 5 to 30 minutes, etc., but is not limited thereto.

[0111] The washing can also be performed by filtering the particles through a filter without centrifuging. The filter may have pores with a diameter equal to or smaller than that of the porous silica particles. When the reaction solution is filtered through such a filter, only the particles remain on the filter, and the filter can be washed by pouring water and / or an organic solvent onto the filter.

[0112] In the washing, water and an organic solvent may be used alternately once or several times, or water or an organic solvent may be used alone once or several times. The number of times may be, for example, 2 to 10 times, for example, 3 to 10 times, 4 to 8 times, or 4 to 6 times.

[0113] The drying can be carried out, for example, at 20° C. to 100° C., but is not limited thereto, and can also be carried out in a vacuum state.

[0114] The particles obtained can then be calcined. Calcination is a process in which the particles are heated to remove silanol groups on the surface and inside to reduce the reactivity of the particles, form a denser structure, and remove organic matter filling the pores. Calcination can be performed, for example, at a temperature of 400°C or higher. The upper limit is not particularly limited, and may be, for example, 1,000°C, 900°C, 800°C, 700°C, etc. Heating can be performed, for example, for 3 hours or more, 4 hours or more, etc. The upper limit is not particularly limited, and may be, for example, 24 hours, 12 hours, 10 hours, 8 hours, 6 hours, 5 hours, etc. More specifically, calcination can be performed at 400°C to 700°C for 3 hours to 8 hours, specifically at 500°C to 600°C for 4 hours to 5 hours, but is not limited thereto.

[0115] Removal of the pore-filling organic matter can prevent problems such as cytotoxicity, foaming, etc., exhibited by remaining organic matter.

[0116] The resulting porous silica particles can then be surface modified. The surface modification can be performed on the surface and / or inside the pores. The particle surface and the inside of the pores can be surface modified in the same way or differently.

[0117] The surface modification can cause the particles to be charged or to have hydrophilic and / or hydrophobic properties.

[0118] More specifically, in order to effectively carry a nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA, the surface of the porous silica particles can be modified to have at least one substituent selected from the group consisting of an amino group, an aminoalkyl group, an alkylamino group, a heterocyclic aromatic compound group containing a nitrogen atom, a cyanide group, and a guanidine group.

[0119] The surface modification can be carried out, for example, by reacting the particles with a compound having a substituent such as hydrophilic, hydrophobic, cationic, or anionic to be introduced. The compound may be, for example, an alkoxysilane having a C1 to C10 alkoxy group, but is not limited thereto.

[0120] The alkoxysilane has one or more alkoxy groups, for example, 1 to 3 alkoxy groups, and may have a substituent to be introduced at a site where an alkoxy group is not bonded, or may have a substituent substituted therewith.

[0121] When the alkoxysilane is reacted with the porous silica particles, a covalent bond between a silicon atom and an oxygen atom is formed, and the alkoxysilane can be bonded to the surface and / or inside of the pores of the porous silica particles. Since the alkoxysilane has a substituent to be introduced, the substituent can be introduced to the surface and / or inside of the pores of the porous silica particles.

[0122] The reaction can be carried out by reacting porous silica particles dispersed in a solvent with an alkoxysilane.

[0123] The solvent may be water and / or an organic solvent. Examples of the organic solvent include ethers (particularly cyclic ethers) such as 1,4-dioxane, halogenated hydrocarbons such as chloroform, methylene chloride, carbon tetrachloride, 1,2-dichloroethane, dichloroethylene, trichloroethylene, perchloroethylene, dichloropropane, amyl chloride, and 1,2-dibromoethane, ketones such as acetone, methyl isobutyl ketone, γ-butyrolactone, 1,3-dimethyl-imidazolidinone, methyl ethyl ketone, cyclohexanone, cyclopentanone, and 4-hydroxy-4-methyl-2-pentanone, carbon-based aromatics such as benzene, toluene, xylene, and tetramethylbenzene, alkylamides such as N,N-dimethylformamide, N,N-dibutylformamide, N,N-dimethylacetamide, and N-methylpyrrolidone, alcohols such as methanol, ethanol, propanol, and butanol, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, ethylene glycol monobutyl ether, and diethylene glycol. Glycol ethers such as monoethyl ether, diethylene glycol monomethyl ether, diethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, dipropylene glycol diethyl ether, and triethylene glycol monoethyl ether (cellosolve); and other dimethylacetamide (DMAc), N,N-diethylacetamide, dimethylformamide (DMF), diethylformamide (DEF), N,N-dimethylacetamide (DMAc), N-methylpyrrolidone (NMP), N-ethylpyrrolidone (NEP), 1,3-dimethyl-2-imidazolidinone, N,N-dimethylmethoxyacetamide, dimethylsulfoxide, pyridine, dimethylsulfone, hexamethylphosphoramide, tetramethylurea, N-methylcaprolactam, tetrahydrofuran, m-dioxane, p-dioxane, and 1,2-dimethoxyethane can be used. Specifically, toluene can be used, but the present invention is not limited to these.

[0124] The positive charge can be produced by reacting with an alkoxysilane having a basic group, such as a nitrogen-containing group, for example, an amino group or an aminoalkyl group. Specifically, N-[3-(trimethoxysilyl)propyl]ethylenediamine, N1-(3-trimethoxysilylpropyl)diethylenetriamine, (3-aminopropyl)trimethoxysilane, N-[3-(trimethoxysilyl)propyl]aniline, trimethoxy[3-(methylamino)propyl]silane, 3-(2-aminoethylamino)propyldimethoxymethylsilane, and the like can be used, but are not limited thereto.

[0125] The negative charge can be produced by reacting with an alkoxysilane having an acidic group such as a carboxy group, a sulfonic acid group, a thiol group, etc. Specifically, (3-mercaptopropyl)trimethoxysilane can be used, but is not limited thereto.

[0126] The charging to an uncharged state (a state in which there is no charge, neither positive nor negative) can be performed by reacting with an alkoxysilane having a normal functional group that does not have a charge, and the charging to a positive charge and the charging to a negative charge can be appropriately combined to charge to an uncharged state due to the cancellation of the positive charge and the negative charge, but the present invention is not limited to this.

[0127] The hydrophilic property can be imparted by reacting with an alkoxysilane having a hydrophilic group, such as a hydroxy group, a carboxy group, an amino group, a carbonyl group, a sulfhydryl group, a phosphate group, a thiol group, an ammonium group, an ester group, an imide group, a thioimide group, a keto group, an ether group, an indene group, a sulfonyl group, a polyethylene glycol group, or the like. Specifically, N-[3-(trimethoxysilyl)propyl]ethylenediamine, N1-(3-trimethoxysilylpropyl)diethylenetriamine, (3-aminopropyl)trimethoxysilane, (3-mercaptopropyl)trimethoxysilane, trimethoxy[3-(methylamino)propyl]silane, 3-(2-aminoethylamino)propyldimethoxymethylsilane, and the like can be used, but are not limited thereto.

[0128] The hydrophobic property can be imparted by reacting with an alkoxysilane having a hydrophobic substituent, for example, a substituted or unsubstituted C1 to C30 alkyl group, a substituted or unsubstituted C3 to C30 cycloalkyl group, a substituted or unsubstituted C6 to C30 aryl group, a substituted or unsubstituted C2 to C30 heteroaryl group, a halogen group, a C1 to C30 ester group, a halogen-containing group, or the like. Specifically, trimethoxy(octadecyl)silane, trimethoxy-n-octylsilane, trimethoxy(propyl)silane, isobutyl(trimethoxy)silane, trimethoxy(7-octen-1-yl)silane, trimethoxy(3,3,3-trifluoropropyl ... Examples of silanes that can be used include, but are not limited to, 3-(trimethoxysilyl)propyl]trithiocarbonate, (3-bromopropyl)trimethoxysilane, and the like.

[0129] In addition, the surface modification can be performed so that hydrophobic substituents are present inside the pores to strengthen the binding strength with nucleic acid molecules or substances that bind complementarily to at least a portion of the poorly soluble (hydrophobic) TSLP mRNA, and treatments can be performed so that hydrophilic substituents are present on the surface of the particles for ease of use and formulation, and substituents for binding nucleic acid molecules or substances that bind complementarily to at least a portion of other TSLP mRNAs may also be present on the surface.

[0130] The surface modification can also be performed in a composite manner. For example, the surface modification can be performed two or more times on the outer surface or inside the pores. As a specific example, a positively charged particle can be modified to have other surface characteristics by bonding a compound containing a carboxyl group to silica particles having an amino group introduced therein through an amide bond, but the surface modification can be performed in a non-limiting manner.

[0131] The reaction of the porous silica particles with alkoxysilane can be carried out, for example, under heating. Heating can be carried out, for example, at 80°C to 180°C, for example, within the above range, such as 80°C to 160°C, 80°C to 150°C, 100°C to 160°C, 100°C to 150°C, or 110°C to 150°C, but is not limited thereto.

[0132] The reaction of the porous silica particles with the alkoxysilane can be carried out for, for example, 4 hours to 20 hours, for example, within the above range, 4 hours to 18 hours, 4 hours to 16 hours, 6 hours to 18 hours, 6 hours to 16 hours, 8 hours to 18 hours, 8 hours to 16 hours, 8 hours to 14 hours, 10 hours to 14 hours, etc., but is not limited to these.

[0133] The reaction temperature, time, and amount of the compound used for surface modification can be selected according to the degree of surface modification. The release rate of the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA can be controlled by changing the reaction conditions according to the degree of hydrophilicity, hydrophobicity, and charge of the nucleic acid molecule or substance of the present invention, thereby controlling the degree of hydrophilicity, hydrophobicity, and charge of the porous silica particles. For example, when the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA is strongly negatively charged at neutral pH, the reaction temperature can be increased, the reaction time can be extended, or the amount of the compound can be increased in order to make the porous silica particles strongly positively charged, but is not limited thereto.

[0134] The porous silica particles of the present invention may be produced, for example, through steps of producing particles with small pores, expanding the pores, modifying the surface, and modifying the inside of the pores.

[0135] The small pore particles can be produced and the pore expanding process can be carried out by the same process as described above, and after the small pore particles are produced and after the pore expanding process, washing and drying processes can be carried out.

[0136] If necessary, washing can be preceded by separation of unreacted substances, for example by centrifugation to separate the supernatant.

[0137] The centrifugation can be carried out at, for example, 6,000 to 10,000 rpm for a period of time of, for example, 3 to 60 minutes, specifically, within the above range, 3 to 30 minutes, 3 to 30 minutes, 5 to 30 minutes, etc., but is not limited thereto.

[0138] The washing of the small pore particles after production can be carried out by the methods / conditions exemplified above, but is not limited thereto.

[0139] The washing after the pore expansion may be performed under less stringent conditions than those exemplified above, for example, washing may be performed up to three times, but is not limited thereto.

[0140] The surface modification and the pore interior modification can be carried out by the same process as described above. The surface modification and the pore interior modification can be carried out in that order, and a step of washing the particles can be further carried out between the two processes.

[0141] If washing is performed under milder conditions after the production of the small pore particles and the expansion of the pores, the inside of the pores will be filled with the reaction liquid, such as the surfactant, used in the production of the particles and the expansion of the pores, so that only the surface may be modified without modifying the inside of the pores during the surface modification.Then, by washing the particles, the reaction liquid inside the pores may be removed.

[0142] The washing of the particles between the surface modification step and the pore interior modification step can be carried out with water and / or an organic solvent. Specifically, since different solvents can dissolve different substances, water and an organic solvent can be used alternately once or several times, or water or an organic solvent can be used alone once or several times. The number of times can be, for example, 2 to 10 times, specifically, 3 to 10 times, 4 to 8 times, 4 to 6 times, etc.

[0143] The washing can be performed under centrifugation, for example, at 6,000 to 10,000 rpm, for a period of time of, for example, 3 to 60 minutes, specifically, within the above range, for example, 3 to 30 minutes, 3 to 30 minutes, 5 to 30 minutes, etc., but is not limited thereto.

[0144] The washing can also be performed by filtering the particles through a filter without centrifuging. The filter may have pores with a diameter equal to or smaller than that of the porous silica particles. When the reaction solution is filtered through such a filter, only the particles remain on the filter, and the filter can be washed by pouring water and / or an organic solvent onto the filter.

[0145] In the washing, water and an organic solvent may be used alternately once or several times, or water or an organic solvent may be used alone once or several times. The number of times may be, for example, 2 to 10 times, specifically, 3 to 10 times, 4 to 8 times, or 4 to 6 times.

[0146] The drying can be carried out, for example, at 20° C. to 100° C., but is not limited thereto, and can also be carried out in a vacuum state.

[0147] The nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA can be supported on the surface and / or inside the pores of the porous silica particles, for example, by mixing the porous silica particles in a solvent with the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA.

[0148] The solvent may be water and / or an organic solvent. Examples of the organic solvent include ethers (particularly cyclic ethers) such as 1,4-dioxane, halogenated hydrocarbons such as chloroform, methylene chloride, carbon tetrachloride, 1,2-dichloroethane, dichloroethylene, trichloroethylene, perchloroethylene, dichloropropane, amyl chloride, and 1,2-dibromoethane, ketones such as acetone, methyl isobutyl ketone, and cyclohexanone, carbon-based aromatics such as benzene, toluene, and xylene, alkylamides such as N,N-dimethylformamide, N,N-dibutylformamide, N,N-dimethylacetamide, and N-methylpyrrolidone, and alcohols such as methanol, ethanol, propanol, and butanol.

[0149] Furthermore, as the solvent, PBS (phosphate buffered saline), SBF (simulated body fluid), borate-buffered saline, Tris-buffered saline, etc. can also be used.

[0150] The ratio of the porous silica particles to the nucleic acid molecules of the present invention is not particularly limited, and may be, for example, a weight ratio of 1:0.05 to 0.8, for example, within the above range, 1:0.05 to 0.7, 1:0.05 to 0.6, 1:0.1 to 0.8, 1:0.1 to 0.6, 1:0.2 to 0.8, 1:0.2 to 0.6, etc.

[0151] The nucleic acid molecule that binds complementary to at least a portion of the TSLP mRNA supported on the porous silica particles can be released in a gradual manner over an extended period of time. Such slow release can be continuous or discontinuous, linear or non-linear, and can vary due to the characteristics of the porous silica particles and / or their interaction with the nucleic acid molecule that binds complementary to at least a portion of the TSLP mRNA.

[0152] The nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA supported on the porous silica particle is released as the porous silica particle is biodegraded, and the porous silica particle according to the present invention can be gradually degraded to gradually release the nucleic acid molecule that binds complementarily to at least a portion of the supported TSLP mRNA. This can be controlled, for example, by adjusting the surface area, particle size, pore diameter, substituents on the surface and / or inside the pores, the degree of surface compactness, etc. of the porous silica particle, but is not limited thereto.

[0153] In addition, the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA supported on the porous silica particles can be released while diffusing away from the porous silica particles. This is influenced by the relationship between the porous silica particles and the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA, and the release environment of the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA, and this can be adjusted to control the release of the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA. For example, it can be adjusted by strengthening or weakening the binding force between the porous silica particles and the nucleic acid molecule that binds complementarily to at least a portion of the TSLP mRNA by surface modification.

[0154] As a more specific example, when the nucleic acid molecule or substance that binds complementarily to at least a portion of the supported TSLP mRNA is poorly soluble (hydrophobic), the surface and / or inside of the pores of the particle may have a hydrophobic substituent, thereby increasing the binding strength between the porous silica particle and the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA. This allows the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA to be released in a sustained manner. For example, the porous silica particle may be surface-modified with an alkoxysilane that has a hydrophobic substituent.

[0155] As used herein, the term "poorly soluble" includes the meanings insoluble, practically insoluble, or only slightly soluble (in water). This is based on the Pharmaceutical Sciences vol. 18, no. th This is a term defined in the USP, Remington, Mack Publishing Company Edition.

[0156] The poorly soluble substance may have a water solubility of less than 10 g / L, specifically less than 5 g / L, and more specifically less than 1 g / L at 1 atmosphere and 25° C., but is not limited thereto.

[0157] When the nucleic acid molecule or substance that binds complementarily to at least a portion of the supported TSLP mRNA is water-soluble (hydrophilic), the surface and / or inside of the pores of the particle may have hydrophilic substituents, which may increase the binding strength between the porous silica particle and the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA. This allows the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA to be released in a sustained manner. For example, the porous silica particle may be surface-modified with an alkoxysilane that has a hydrophilic substituent.

[0158] The water-soluble substance may have a water solubility of 10 g / L or more at 1 atmosphere and 25° C., but is not limited thereto.

[0159] When the nucleic acid molecule or substance that binds complementarily to at least a portion of the carried TSLP mRNA is charged, the surface of the particle and / or the inside of the pores can be charged with the opposite charge, thereby increasing the binding strength between the porous silica particle and the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA. This allows the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA to be released in a sustained manner. For example, the porous silica particle may be surface-modified with an alkoxysilane having an acidic or basic group.

[0160] Specifically, if the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA is positively charged at neutral pH, the surface of the particle and / or the inside of the pores may be negatively charged at neutral pH. This increases the binding strength between the porous silica particle and the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA, allowing the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA to be released in a sustained manner. For example, the porous silica particle may be surface-modified with an alkoxysilane having an acidic group such as a carboxy group (-COOH) or a sulfonic acid group (-SO3H).

[0161] Furthermore, if the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA is negatively charged at neutral pH, the surface of the particle and / or the inside of the pores may be positively charged. This increases the binding strength between the porous silica particle and the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA, allowing the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA to be released in a sustained manner. For example, the porous silica particle may be surface-modified with an alkoxysilane having a basic group such as an amino group or other nitrogen-containing group.

[0162] Nucleic acid molecules or substances that complementarily bind to at least a portion of TSLP mRNA can be released over a period of, for example, 7 days to 1 year or more, depending on the type of treatment required, the release environment, and the porous silica particles used.

[0163] Furthermore, since the porous silica particles of the present invention are biodegradable and can be 100% decomposed, the nucleic acid molecule or substance that binds complementarily to at least a portion of the TSLP mRNA carried thereon can be 100% released.

[0164] The nucleic acid molecule may be one strand of siRNA, dsRNA, PNA, or miRNA. In such cases, the siRNA, dsRNA, PNA, or miRNA may suppress the expression of the TSLP gene by RNAi (RNA interference), more specifically, by binding complementarily to at least a portion of TSLP mRNA to suppress the expression of the TSLP gene.

[0165] Specifically, the nucleic acid molecule includes siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 1 and an antisense RNA having the sequence of SEQ ID NO: 47, dsRNA consisting of a strand having the sequence of SEQ ID NO: 24 and a strand complementary thereto, siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 2 and an antisense RNA having the sequence of SEQ ID NO: 48, dsRNA consisting of a strand having the sequence of SEQ ID NO: 25 and a strand complementary thereto, siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 3 and an antisense RNA having the sequence of SEQ ID NO: 49, dsRNA consisting of a strand having the sequence of SEQ ID NO: 26 and a strand complementary thereto, siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 4 and an antisense RNA having the sequence of SEQ ID NO: 50, dsRNA consisting of a strand having the sequence of SEQ ID NO: 27 and a strand complementary thereto, siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 5 and an antisense RNA having the sequence of SEQ ID NO: 51, dsRNA consisting of a strand having the sequence of SEQ ID NO: 28 and a strand complementary thereto, dsRNA consisting of a sense RNA having the sequence of SEQ ID NO: 6 and an antisense RNA having the sequence of SEQ ID NO: 52, siRNA consisting of antisense RNA, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:29 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:7 and an antisense RNA consisting of the sequence of SEQ ID NO:53, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:30 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:8 and an antisense RNA consisting of the sequence of SEQ ID NO:54, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:31 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:9 and an antisense RNA consisting of the sequence of SEQ ID NO:55, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:32 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:10 and an antisense RNA consisting of the sequence of SEQ ID NO:56, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:33 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:11 and an antisense RNA consisting of the sequence of SEQ ID NO:57, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:34 and a strand complementary thereto,siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 12 and an antisense RNA consisting of the sequence of SEQ ID NO: 58, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 35 and a strand complementary thereto, an siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 13 and an antisense RNA consisting of the sequence of SEQ ID NO: 59, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 36 and a strand complementary thereto, an siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 14 and an antisense RNA consisting of the sequence of SEQ ID NO: 60, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 37 and a strand complementary thereto, an siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 15 and an antisense RNA consisting of the sequence of SEQ ID NO: 61, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 38 and a strand complementary thereto, an siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 16 and an antisense RNA consisting of the sequence of SEQ ID NO: 62, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 39 and a strand complementary thereto, a sense RNA consisting of the sequence of SEQ ID NO: 17 and an antisense RNA consisting of the sequence of SEQ ID NO: 63 siRNA consisting of a strand having the sequence of SEQ ID NO: 40 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of a sequence of SEQ ID NO: 18 and an antisense RNA consisting of a sequence of SEQ ID NO: 64, dsRNA consisting of a strand having the sequence of SEQ ID NO: 41 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of a sequence of SEQ ID NO: 19 and an antisense RNA consisting of a sequence of SEQ ID NO: 65, dsRNA consisting of a strand having the sequence of SEQ ID NO: 42 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of a sequence of SEQ ID NO: 20 and an antisense RNA consisting of a sequence of SEQ ID NO: 66, dsRNA consisting of a strand having the sequence of SEQ ID NO: 43 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of a sequence of SEQ ID NO: 21 and an antisense RNA consisting of a sequence of SEQ ID NO: 67, dsRNA consisting of a strand having the sequence of SEQ ID NO: 44 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of a sequence of SEQ ID NO: 22 and an antisense RNA consisting of a sequence of SEQ ID NO: 68, dsRNA consisting of a strand having the sequence of SEQ ID NO: 45 and a strand complementary thereto,The siRNA may be one or more of a sense RNA consisting of the sequence of SEQ ID NO: 23 and an antisense RNA consisting of the sequence of SEQ ID NO: 69, or a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 46 and a strand complementary thereto, but is not limited thereto. In Tables 1 and 2 shown below, "Target sequence" means "target sequence", "Position in gene sequence" means "position of gene sequence", "GC content" means "GC content", "Sense strand" means "sense strand", and "Antisense strand" means "antisense strand", respectively.

[0166] [Table 1] JPEG0007580121000002.jpg202149 JPEG0007580121000003.jpg201149 JPEG0007580121000004.jpg204149 JPEG0007580121000005.jpg203149 JPEG0007580121000006.jpg152149

[0167] The nucleic acid molecules of the present invention may be derived from animals, including humans, such as monkeys, pigs, horses, cows, sheep, dogs, cats, mice, rabbits, etc., and preferably from humans.

[0168] The nucleic acid molecule of the present invention is a concept that includes functional equivalents of the nucleic acid molecules that compose it, for example, variants in which a portion of the base sequence of the nucleic acid molecule of the present invention has been altered by deletion, substitution or insertion but which can function in the same way as the nucleic acid molecule of the present invention.

[0169] More specifically, when the nucleic acid molecule of the present invention forms a sense RNA or antisense RNA of siRNA, the sense RNA and antisense RNA sequences may further contain a sequence of UU or dTdT at the 3' end, which can provide siRNA or dsRNA with advantages such as improved structural stability of siRNA or dsRNA due to increased resistance to nuclease enzymes, and improved RNAi efficiency of siRNA or dsRNA due to stable induction of RISC.

[0170] The nucleic acid molecule of the present invention can be isolated or produced using standard molecular biology techniques, such as chemical synthesis or recombinant methods, or can be commercially available. In addition, the composition of the present invention can contain not only the nucleic acid molecule of the present invention itself, but also other substances that can increase the expression rate of the nucleic acid molecule of the present invention in cells, such as compounds, natural products, novel proteins, etc.

[0171] Alternatively, the nucleic acid molecules of the invention can be provided in a vector for intracellular expression.

[0172] The nucleic acid molecule of the present invention can be introduced into cells using various transformation techniques, such as a complex of DNA and DEAE-dextran, a complex of DNA and nucleoprotein, or a complex of DNA and lipid. To this end, the nucleic acid molecule of the present invention may be contained in a delivery vehicle that allows efficient introduction into cells. The delivery vehicle is preferably a vector, and both viral and non-viral vectors can be used. As the viral vector, for example, lentivirus, retrovirus, adenovirus, herpes virus, and avipox virus vectors can be used, and preferably, but are not limited to, lentivirus vectors. Lentivirus is a type of retrovirus, and has the characteristic of infecting not only dividing cells but also non-dividing cells due to the nucleophilicity of the pre-integrated complex (virus "shell") that allows active introduction into the nuclear pore or the intact nuclear membrane.

[0173] In addition, it is preferable that the vector containing the nucleic acid molecule of the present invention further contains a selection marker. The "selection marker" is intended to facilitate the selection of cells into which the nucleic acid molecule of the present invention has been introduced. The selection marker that can be used in the vector is not particularly limited as long as it is a gene that can easily detect or measure the presence or absence of the introduction of the vector. Representative examples of the selection marker include markers that confer a selectable phenotype such as drug resistance, auxotrophy, resistance to cytotoxic agents, or expression of a surface protein, for example, GFP (green fluorescent protein), puromycin, neomycin (Neo), hygromycin (Hyg), histidinol dehydrogenase gene (hisD), and guanine phosphoribosyltransferase (Gpt), and preferably, GFP (green fluorescent protein) and puromycin markers can be used.

[0174] The present invention also provides a pharmaceutical composition for preventing or treating atopic diseases, comprising: a composition for inhibiting TSLP gene expression, comprising porous silica particles carrying a nucleic acid molecule that binds complementarily to at least a portion of the above-mentioned TSLP mRNA.

[0175] Specific details regarding the nucleic acid molecules, porous silica particles, inhibition of TSLP gene expression, etc. are as described above.

[0176] The pharmaceutical composition of the present invention has an effect of preventing or treating atopic diseases, and this effect can be achieved by suppressing the expression of the TSLP gene by the nucleic acid molecule of the present invention.

[0177] Examples of atopic diseases that are targets for prevention or treatment with the pharmaceutical compositions of the present invention include at least one disease selected from the group consisting of allergic diseases such as bronchial asthma, allergic rhinitis, urticaria, atopic dermatitis, allergic conjunctivitis, allergic dermatitis, allergic contact dermatitis, inflammatory skin diseases, pruritus, and food allergies, but are not limited thereto, and are not particularly limited as long as they are diseases caused by overexpression of TSLP.

[0178] "Atopic dermatitis" refers to a condition in which the skin has become infected with atopic dermatitis. This condition includes both conditions that are considered to be skin diseases and conditions that are not considered to be skin diseases.

[0179] The pharmaceutical composition of the present invention may further include a pharma- ceutically acceptable carrier and may be formulated together with a carrier. In the present invention, the term "pharma- ceutically acceptable carrier" refers to a carrier or diluent that does not stimulate the organism and does not inhibit the biological activity and properties of the administered compound. In the composition formulated into a liquid solution, the pharma- ceutical acceptable carrier may be a mixture of saline, sterile water, Ringer's solution, buffered saline, albumin injection, dextrose solution, maltodextrin solution, glycerol, ethanol, or one or more of these components, which are sterile and suitable for the body, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, the composition may be formulated into an injectable dosage form such as an aqueous solution, suspension, or emulsion, or into pills, capsules, granules, or tablets by additionally adding a diluent, dispersant, surfactant, binder, and lubricant.

[0180] The pharmaceutical composition of the present invention can be applied to any dosage form containing the nucleic acid molecule of the present invention as an active ingredient, and can be prepared into oral or parenteral dosage forms. The pharmaceutical dosage forms of the present invention include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), subcutaneous, vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration, or forms suitable for administration by inhalation or insufflation.

[0181] The pharmaceutical composition of the present invention is administered in a pharmacologic effective amount. The effective dose can be determined by factors including the type and severity of the patient's disease, the activity of the drug, the sensitivity to the drug, the administration time, the administration route, the excretion rate, the duration of treatment, and other factors well known in the medical field. The pharmaceutical composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents. It can also be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or multiple times. It is important to administer an amount that provides maximum effect at a minimum amount without side effects, taking into consideration all of the above factors, and this can be easily determined by those skilled in the art.

[0182] The dosage of the pharmaceutical composition of the present invention varies widely depending on the patient's body weight, age, sex, health condition, food, administration time, administration method, excretion rate, and severity of the disease. The appropriate dosage may vary, for example, depending on the amount of drug accumulated in the patient's body and / or the specific efficacy of the nucleic acid molecule of the present invention used. In general, it can be calculated based on the EC50 determined to be effective in in vivo animal models and in vitro, and may be, for example, 0.01 μg to 1 g per kg of body weight. It may be administered once or several times per unit period of days, weeks, months, or years, or it may be administered continuously for a long period of time using an infusion pump. The number of repeated administrations is determined taking into consideration the residence time of the drug in the body, the drug concentration in the body, etc. Depending on the course of treatment of the disease, the composition can be administered to prevent recurrence even after treatment.

[0183] The pharmaceutical composition of the present invention may further contain one or more active ingredients exhibiting the same or similar functions in relation to the treatment of atopic diseases, or compounds that maintain / increase the solubility and / or absorbability of the active ingredients, and may further contain chemotherapeutic agents, anti-inflammatory agents, antiviral agents, and / or immunomodulatory agents, etc., as necessary.

[0184] In addition, the pharmaceutical composition of the present invention can be formulated by a method known in the art so as to provide a quick, sustained or delayed release of the active ingredient after administration to a mammal. The dosage form may be in the form of powder, granule, tablet, emulsion, syrup, aerosol, soft or hard gelatin capsule, sterile injection solution or sterile powder.

[0185] Furthermore, the present invention provides a cosmetic composition for preventing or ameliorating atopic diseases, comprising: a composition for inhibiting TSLP gene expression, comprising porous silica particles carrying a nucleic acid molecule that binds complementarily to at least a portion of the above-mentioned TSLP mRNA.

[0186] Details of the nucleic acid molecule, porous silica particles, inhibition of TSLP gene expression, atopic diseases, etc. are as described above.

[0187] The cosmetic composition of the present invention has the effect of preventing or improving atopic diseases, and this effect can be achieved by suppressing the expression of the TSLP gene by the nucleic acid molecule of the present invention.

[0188] The cosmetic composition of the present invention may further contain ingredients that are commonly used in cosmetic compositions, for example, conventional adjuvants and carriers such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances, but are not limited thereto.

[0189] Examples of products to which the composition can be added include cosmetics such as astringent lotions, softening lotions, nourishing lotions, various creams, essences, packs, and foundations, as well as cleansers, facial washes, soaps, treatments, and beauty serums, but are not limited to these.

[0190] Specific dosage forms of the cosmetic composition of the present invention may include, but are not limited to, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, essence, nourishing essence, pack, soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, lipstick, makeup base, foundation, pressed powder, loose powder, eye shadow, and the like.

[0191] The present invention also relates to a method for treating atopic diseases.

[0192] The method for treating an atopic disease of the present invention comprises administering to an individual porous silica particles carrying a substance that suppresses the expression of TSLP.

[0193] The substance that inhibits the expression of TSLP may be within the ranges described above.

[0194] The porous silica particles may be within the range exemplified above, or may be produced by the method / conditions etc. within the range exemplified above.

[0195] The individual may be a mammal, including a human, and may specifically be a human.

[0196] The substance that inhibits the expression of TSLP can be formulated in the form of a composition by a method within the range described above.

[0197] The method of administration is not limited, and may be, for example, a method suitable for oral, rectal, nasal, topical (including buccal and sublingual), subcutaneous, vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration, or a method for administration by inhalation or insufflation.

[0198] The present invention also relates to the use of porous silica particles carrying a substance that inhibits the expression of TSLP for producing a pharmaceutical composition for preventing or treating atopic diseases.

[0199] The substance that inhibits the expression of TSLP may be within the ranges described above.

[0200] The porous silica particles may be within the range exemplified above, or may be produced by the method / conditions etc. within the range exemplified above.

[0201] The present invention will now be described in detail with reference to examples.

[0202] Hereinafter, the siRNA used in the present invention may be abbreviated as "siTSLP," the porous silica particles of the present invention may be abbreviated as "DegradaBALL or DDV," and DegradaBALL carrying siTSLP may be abbreviated as "LEM-siTSLP."

[0203] Experimental Method 1. Experimental Materials DegradaBALL and TAMRA-conjugated DegradaBALL were provided by Lemonex, Inc. (Seoul, Republic of Korea). Cell counting kit-8 was purchased from Dojindo molecular technologies, Inc. (Maryland, USA). 10% phosphate-buffered saline (PBS), Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), Roswell Park Memorial Institute 1640 (RPMI 1640), penicillin-streptomycin, and 0.05% trypsin-EDTA were purchased from WelGene (Republic of Korea). PCR primers were all purchased from Cosmogenetech (Seoul, Republic of Korea). Trizol cell lysis solution was purchased from Molecular Probes Invitrogen (Carlsbad, CA, USA). PCR reagents were all purchased from TaKaRa Bio Inc. (Shiga, Japan). All chemicals were used as received.

[0204] The SLIGRL peptide used to induce the expression of TSLP was synthesized by Lemonex (Seoul, Republic of Korea). The results of MS analysis of the synthesized peptide are shown in Figure 1.

[0205] The nucleotide sequence can be searched at the National Center for Bioinformation (http: / / www.ncbi.nim.nih.gov) and is listed under the official symbol (TSLP) and the official name thymic stromal lymphopoietin. siRNA, dsRNA, and antisense RNA sequences against human TSLP were designed using the human sequence with the approval number NM_033035.4. siRNA was designed through the Dharmacon RNAi & Gene Expression service at GE Healthcare (http: / / dharmacon.gelifesciences.com / designcenter / ?redirect=true), an internet site that provides siRNA design. At this time, 10 sequences, from siRNA sequence 1 to sequence 10, in which the GC content of the target sequence is 30% to 70% were selected from the designed DNA fragments. In addition, the inventor designed 13 sequences, from sequence 11 to sequence 23, as siRNA sequences with a GC content of 30% to 70%. The final 23 selected siRNAs were made by order from Bioneer (http: / / www.bioneer.co.kr). At this time, sense and antisense sequences for the target sequence of TSLP were designed for the siRNA production. In addition, siRNA and dsRNA were produced by specific base pairing between the sense and antisense sequences, which are each a single sequence.

[0206] Specific information of the above described sequences is specifically shown in the attached sequence listing and Table 2 below.

[0207] [Table 2] JPEG0007580121000008.jpg203149 JPEG0007580121000009.jpg233148 JPEG0007580121000010.jpg240149 JPEG0007580121000011.jpg241150 JPEG0007580121000012.jpg167150

[0208] 2. Porous Silica Particles (DDV or DegradaBALL) 2-1. Production of porous silica particles (1) Preparation of porous silica particles 1) Production of small-pore particles A 2L round-bottom flask was charged with 960ml of distilled water (DW) and 810ml of MeOH. 7.88g of CTAB was added to the flask, and 4.52ml of 1M NaOH was quickly added while stirring. After stirring for 10 minutes to obtain a uniform mixture, 2.6ml of TMOS was added. After stirring for 6 hours to obtain a uniform mixture, the mixture was aged for 24 hours to obtain a reaction solution. Thereafter, the reaction solution was centrifuged at 8,000 rpm for 10 minutes at 25° C. to remove the supernatant, and the mixture was centrifuged at 8,000 rpm for 10 minutes at 25° C. and washed alternately five times with ethanol and distilled water. Thereafter, it was dried in an oven at 70° C. to obtain 1.5 g of powdered small-pore porous silica particles (average pore diameter: 2 nm, particle size: 200 nm).

[0209] 2) Stoma expansion 1.5 g of small pore porous silica particle powder was added to 10 ml of ethanol and ultrasonically dispersed, and then 10 ml of water and 10 ml of TMB (trimethyl benzene) were added and ultrasonically dispersed to obtain a dispersion. Thereafter, the dispersion was placed in an autoclave and reacted at 160° C. for 48 hours. The reaction was started at 25° C., and the temperature was raised at a rate of 10° C. / min. Then, the mixture was gradually cooled in the autoclave at a rate of 1 to 10° C. / min. The cooled reaction solution was centrifuged at 8,000 rpm for 10 min at 25°C, the supernatant was removed, and the mixture was centrifuged at 8,000 rpm for 10 min at 25°C and washed alternately five times with ethanol and distilled water. It was then dried in an oven at 70°C to obtain powdered porous silica particles (pore diameter 10 to 15 nm, particle size 200 nm).

[0210] 3) Calcination The porous silica particles prepared in 2) were placed in a glass vial and heated at 550° C. for 5 hours. After the reaction was completed, the mixture was gradually cooled to room temperature to prepare particles.

[0211] (2) Preparation of porous silica particles Porous silica particles were produced in the same manner as in the above-mentioned method 2-1-(1), except that the reaction conditions for pore expansion were changed to 140° C. and 72 hours.

[0212] (3) Production of porous silica particles (10 L scale) Porous silica particles were produced in the same manner as in Example 2-1-(1), except that a vessel five times larger was used and five times the volume of each substance was used.

[0213] (4) Production of porous silica particles (particle size 300 nm) Porous silica particles were produced in the same manner as in 2-1-(1), except that 920 ml of distilled water and 850 ml of methanol were used in producing the small-pore particles.

[0214] (5) Production of porous silica particles (particle size 500 nm) Porous silica particles were produced in the same manner as in 2-1-(1), except that 800 ml of distilled water, 1,010 ml of methanol, and 10.6 g of CTAB were used in producing the small-pore particles.

[0215] (6) Production of porous silica particles (particle size 1,000 nm) Porous silica particles were produced in the same manner as in 2-1-(1), except that 620 ml of distilled water, 1,380 ml of methanol, and 7.88 g of CTAB were used in producing the small-pore particles.

[0216] (7) Preparation of porous silica particles (pore diameter 4 nm) Porous silica particles were produced in the same manner as in 2-1-(1), except that 2.5 ml of TMB was used during pore expansion.

[0217] (8) Preparation of porous silica particles (pore diameter 7 nm) Porous silica particles were produced in the same manner as in 2-1-(1), except that 4.5 ml of TMB was used during pore expansion.

[0218] (9) Preparation of porous silica particles (pore diameter 17 nm) Porous silica particles were produced in the same manner as in 2-1-(1), except that 11 ml of TMB was used during pore expansion.

[0219] (10) Preparation of porous silica particles (pore diameter 23 nm) Porous silica particles were produced in the same manner as in 2-1-(1), except that 12.5 ml of TMB was used during pore expansion.

[0220] (11) Preparation of Porous Silica Particles (Double Modification) 1) Production of small-pore particles Small-pore particles were produced in the same manner as in Example 2-1-(1)-1).

[0221] 2) Stoma expansion The small pore particles were reacted with TMB in the same manner as in Example 2-1-(1)-2), cooled, and centrifuged to remove the supernatant. Then, the particles were centrifuged under the same conditions as in Example 2-1-(1)-2), and washed three times alternately with ethanol and distilled water. Then, the particles were dried under the same conditions as in Example 2-1-(1)-2) to obtain powdered porous silica particles (pore diameter 10-15 nm, particle size 200 nm).

[0222] 3) Surface modification 0.8g to 1g of porous silica particles with expanded pores were dispersed in 50ml of toluene, and then 5ml of (3-aminopropyl)triethoxysilane was added and heated at 120℃ under reflux for 12 hours. In this process, after the above-mentioned washing and drying processes, 1ml of triethylene glycol (PEG3,2-[2-(2-methoxyethoxy)ethoxy]acetic acid), 100mg of EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide), and 200mg of N-hydroxysuccinimide (NHS) were dispersed in 30ml of PBS and reacted for 12 hours with stirring at room temperature. The product then went through the above-mentioned washing and drying processes. Since the reaction liquid from the previous step remains inside the pores, the inside of the pores is not modified.

[0223] 4) Cleaning the inside of the pores 800 mg of the surface-modified particle powder was dissolved in 40 ml of 2M HCl / ethanol and refluxed under strong stirring for 12 hours. The cooled reaction solution was then centrifuged at 8,000 rpm for 10 min to remove the supernatant, centrifuged at 8,000 rpm for 10 min at 25°C, and washed alternately five times with ethanol and distilled water. Thereafter, it was dried in an oven at 70° C. to obtain powdered porous silica particles.

[0224] 5) Pore interior modification i) Propyl groups were introduced into the pores in the same manner as in Example 2-2-(2)-1) described below. ii) Octyl groups were introduced into the pores in the same manner as in Example 2-2-(2)-2) described below.

[0225] 2-2. Surface modification of porous silica particles (1) Charging with a positive charge 1) Particles with a diameter of 300 nm The porous silica particles of Example 2-1-(4) were reacted with (3-aminopropyl)triethoxysilane (APTES) to be positively charged. Specifically, 100 mg of porous silica particles were dispersed in 10 mL of toluene in a 100 mL round-bottom flask using a bath sonicator, and then 1 mL of APTES was added and stirred at 400 rpm and 130° C. for 12 hours. After the reaction, the mixture was gradually cooled to room temperature, centrifuged at 8,000 rpm for 10 minutes to remove the supernatant, centrifuged at 8,000 rpm at 25° C. for 10 minutes, and washed alternately five times with ethanol and distilled water. Thereafter, the mixture was dried in an oven at 70° C. to obtain powdered porous silica particles having amino groups on the surface and inside the pores.

[0226] 2) Particles with a diameter of 200 nm i) The porous silica particles of Example 2-1-(1) were reacted with (3-aminopropyl)triethoxysilane (APTES) to give them a positive charge, and modified in the same manner as in Example 2-2-(1)-1) except that 0.4 ml of APTES was added and the reaction time was 3 hours. ii) The porous silica particles of Example 2-1-(9) were reacted with (3-aminopropyl)triethoxysilane (APTES) to give them a positive charge, and otherwise modified in the same manner as in Example 2-2-(1)-1). iii) The porous silica particles of Example 2-1-(10) were reacted with (3-aminopropyl)triethoxysilane (APTES) to give them a positive charge, and otherwise modified in the same manner as in Example 2-2-(1)-1).

[0227] (2) Introduction of hydrophobic groups 1) Propyl group The porous silica particles of Example 2-1-(1) were modified in the same manner as in Example 2-2-(1) above, except that the particles were reacted with trimethoxy(propyl)silane to introduce propyl groups onto the surface and inside the pores, 0.35 ml of trimethoxy(propyl)silane was added instead of APTES, and the reaction was carried out for 12 hours.

[0228] 2) Octyl group The porous silica particles of Example 2-1-(1) were modified in the same manner as in Example 2-2-(1) above, except that propyl groups were introduced onto the surface and inside the pores by reacting the particles with trimethoxy-n-octylsilane, 0.5 ml of trimethoxy-n-octylsilane was added instead of APTES, and the reaction was carried out for 12 hours.

[0229] (3) Charging with a negative charge 1) Carboxyl group The porous silica particles of Example 2-1-(1) were reacted with succinic anhydride to be negatively charged, and DMSO (dimethyl sulfoxide) was used instead of toluene, 80 mg of succinic anhydride was added instead of APTES, and the mixture was stirred at room temperature for 24 hours to react. The particles were modified in the same manner as in Example 2-2-(1)-1), except that DMSO was used instead of distilled water during washing.

[0230] 2) Thiol group The modification was carried out in the same manner as in Example 2-2-(1)-1) above, except that 1.1 mL of MPTES was used instead of APTES.

[0231] 3) Sulfonic acid group 100 mg of the porous silica nanoparticles of Example 2-2-(3)-2) were dispersed in 1 mL of 1 M sulfuric acid aqueous solution and 20 mL of 30% hydrogen peroxide solution, and stirred at room temperature to induce an oxidation reaction to oxidize the thiol group to a sulfonic acid group. Then, the nanoparticles were washed and dried in the same manner as in Example 2-2-(1)-1).

[0232] 3. Carrying of Nucleic Acid Molecules 10 μg of the porous silica particles of Example 2-2-(1)-2)-ii) and 50 pmol of the nucleic acid molecule were mixed in 1×PBS and then allowed to stand at room temperature for 30 minutes for loading. The following experiments were carried out using the nucleic acid molecules, which are siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 70 and an antisense RNA consisting of the sequence of SEQ ID NO: 93 (hereinafter referred to as siTSLP#1), siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 83 and an antisense RNA consisting of the sequence of SEQ ID NO: 106 (hereinafter referred to as siTSLP#14), and / or siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 90 and an antisense RNA consisting of the sequence of SEQ ID NO: 113 (hereinafter referred to as siTSLP#21) from the sequences in Table 2. However, when a separate reference is made to a sequence (e.g., sense RNA, antisense RNA, dsRNA) constituting a nucleic acid molecule in the contents described below, it can be considered as carrying a nucleic acid molecule containing the separately mentioned sequence. In the following, DDV carrying siTSLP#1 is represented as LEM-siTSLP#1, DDV carrying siTSLP#14 as LEM-siTSLP#14, and DDV carrying siTSLP#21 as LEM-siTSLP#21.

[0233] 4. Measuring Cell Viability A549 and HaCaT cells were seeded at a density of 10,000 cells per well in a 96-well culture plate with 100 μl of growth medium (50-70% confluent). The cells were treated with an appropriate concentration of DegradaBALL (porous silica particles of Example 2-2-(1)-2)-ii in serum-containing medium and cultured at 37°C for 24 hours. After the culture, the cells were washed twice with 1xPBS, and then 100 μl of serum-free medium containing 10 μl of CCK-8 was added and cultured for another hour. The optical density of each well in the culture plate was measured at a wavelength of 450 nm. The mean and standard deviation of the triplicates were calculated and plotted (see FIG. 26).

[0234] 5. Cell-based TSLP knockdown analysis 5-1. Cultivation of human skin keratinocyte cell line HaCaT cells To investigate whether human TSLP-specific siRNA, dsRNA, or antisense RNA oligonucleotides can inhibit the production of TSLP in skin cells, we used the human skin keratinocyte HaCaT cell line (CLC cell line service, Germany). The HaCaT cell line was cultured in DMEM medium (Gibco BRL, USA) containing 10% fetal bovine serum (FBS; Gibco BRL, USA) and antibiotics. The cells were cultured in 100-mm culture dishes, 6-well plates, and 24-well plates in an incubator at 37°C with 5% CO2. The medium was changed every 2 days, and the cells were subcultured just before overgrowth.

[0235] 5-2.Treatment of HaCaT cells with LEM-siTSLP HaCaT cells cultured in a 24-well plate were treated with LEM-siTSLP (25 pmol) dispersed in serum-free medium. After 6 hours of culture in a 37°C, 5% CO2 incubator, the serum-free medium was removed. After washing twice with 1xPBS, serum-containing cell medium was replaced. After another 6 hours, serum-containing culture medium was removed and washed with 1xPBS. The cells were treated with SLIGRL peptide (200 μM) in serum-containing medium. To confirm TSLP induction, total RNA was extracted using Trizol (Invitrogen, USA) after 0, 6, 12, and 24 hours of culture.

[0236] To measure the duration of TSLP knockdown by LEM-siTSLP, PAM212 cells were treated with LNP-containing LNP-siTSLP(mouse) (25 pmol siTSLP) and siTSLP(mouse) (25 pmol) in serum-free medium. After 6 hours of culture at 37°C in a 5% CO2 incubator, serum-free medium was removed. After washing twice with 1xPBS, serum-containing cell medium was replaced. After culturing for the indicated time, cells were treated with SLIGRL (200 μM) in serum-containing medium and cultured for an additional 12 hours for TSLP induction. Total RNA was extracted using Trizol.

[0237] 6.RT-PCR 1μg of total RNA was mixed with nuclease-free water to prepare a 16μL solution. The RNA was then denatured by reacting at 70℃ for 5 minutes, and the mixture was quickly cooled on ice and briefly centrifuged to collect the evaporated solution. Then, 4μL of Reverse Transcription Master Premix (Elpis Biotech, contain random hexamer, 5x ready-to-use mix, cat#EBT-1511) was added and mixed well, and the mixture was reacted at 42℃ for 1 hour. The mixture was then reacted at 94℃ for 5 minutes, cooled on ice, and stored at -20℃.

[0238] Next, 7.4 μL of nuclease-free water, 0.8 μL each of forward primer and reverse primer (5 μM), 1 μL of the previously synthesized cDNA template, and 10 μL of Power SYBR® Green PCR Master Mix (appliedbiosystems, 2x ready-to-use mix, cat#4367659) were mixed to prepare a mixed solution.

[0239] The RT-PCR primer sequences used for analysis of mRNA expression levels are shown in Table 3.

[0240] [Table 3]

[0241] After denaturation at 95°C for 3 minutes, PCR was repeated in a two-step cycle of 95°C for 10 seconds and 60°C for 5 seconds (GAPDH: 30 cycles, TSLP: 36 cycles). The final reaction product was subjected to 1% agarose gel for confirmation.

[0242] 7. Imaging of biological tissue at the site where siTSLP and porous silica particles were administered 20 μl of LEM-siTSLP (0.7 nmol siTSLP(mouse), 150 μg DDV) (FITC-conjugated siTSLP(mouse) and TAMRA-DegradaBALL) was injected into the skin of the cheek region of mice. The DDV used was the porous silica particles of Example 2-2-(1)-2)-ii). The siTSLP(mouse) used was one to which a sense RNA sequence (5'-CGAGCAAAUCGAGGACUGUdTdT-3' (SEQ ID NO: 124)) and an antisense RNA sequence (5'-ACAGUCCUCGAUUUGCUCGdTdT-3' (SEQ ID NO: 125)) were bound. After sacrificing the mice, fluorescent images of the excised skin of the cheek region of the mice were taken using a FOBI imaging device (NeoScience Co., Ltd., Seoul, Korea). The obtained skin sample was placed in a 4% PFA solution. The samples were embedded in paraffin and cut to a thickness of 10 μm. After a dehydration process, the sectioned samples were stained with DAPI. The samples were observed under a BX71 microscope equipped with a 20x objective lens (Olympus, Tokyo, Japan).

[0243] Experimental Results 1. Analysis of the Inhibition of TSLP Expression by the Nucleic Acid Molecules of the Present Invention To confirm the TSLP expression inhibition rate of the nucleic acid molecules (siRNA or dsRNA) prepared according to the sequences listed in Table 2, the nucleic acid molecules were transfected into HaCaT cells using Lipofectamine 2000 (Invitrogen, USA) and cationic liposomes, and the TSLP expression inhibition efficiency was then confirmed. The rate of suppression of TSLP expression using nucleic acid molecules (siRNA or dsRNA) is shown in Table 4 below.

[0244] [Table 4]

[0245] 2. Porous Silica Particles (DDV or DegradaBALL) 2-1. Confirmation of particle formation and pore expansion The small-pore particles of the particles in Example 2-1-(1) to (3) of the experimental method and the produced porous silica particles were observed under a microscope to confirm whether the small-pore particles were generated uniformly and whether the pores were sufficiently expanded to form the porous silica particles uniformly (Figures 2 to 5). FIG. 2 is a photograph of the porous silica particles of Example 2-1-(1), and FIG. 3 is a photograph of the porous silica particles of Example 2-1-(2). It can be seen that spherical porous silica particles with sufficiently expanded pores were uniformly produced. FIG. 4 is a photograph of the small-pore particles of Example 2-1-(1), and FIG. 5 is a comparative photograph of the small-pore particles of Examples 2-1-(1) and 2-1-(3). It can be seen that spherical small-pore particles were uniformly produced.

[0246] 2-2. Calculation of BET surface area and pore volume The surface area and pore volume of the small pore particles of Experimental Method Example 2-1-(1) and the porous silica particles of Experimental Method Examples 2-1-(1), (7), (8), and (10) were calculated. The surface area was calculated by the Brunauer-Emmett-Teller (BET) method, and the pore size distribution was calculated by the Barrett-Joyner-Halenda (BJH) method. The micrographs of the particles are shown in FIG. 6, and the calculation results are shown in Table 5 below.

[0247] [Table 5]

[0248] 2-3. Confirmation of biodegradability In order to confirm the biodegradability of the porous silica particles of Example 2-1-(1) of the experimental method, the degree of biodegradation in SBF (pH 7.4) at 37°C was observed under a microscope at 0 hours, 120 hours, and 360 hours. The results are shown in FIG. From this, it can be seen that the porous silica particles were biodegraded, and almost all of them were decomposed after 360 hours.

[0249] 2-4. Measurement of absorbance ratio The absorbance ratio was measured at each time according to the following Equation 1.

[0250] [Formula 1] A t / A0 (In the formula, A0 is the absorbance of the porous silica particles measured by putting 5 ml of a suspension of 1 mg / ml of the porous silica particles into a cylindrical permeable membrane having pores with a diameter of 50 kDa, Outside the permeable membrane, 15 ml of the same solvent as the suspension is placed in contact with the permeable membrane, and the inside and outside of the permeable membrane are horizontally stirred at 60 rpm at 37°C. A t is the absorbance of the porous silica particles measured t hours after the measurement of A0.

[0251] Specifically, 5 mg of porous silica particle powder was dissolved in 5 ml of SBF (pH 7.4). Then, 5 ml of the porous silica particle solution was placed in a permeable membrane with pores of 50 kDa diameter as shown in Figure 8. 15 ml of SBF was added to the outer membrane, and the SBF in the outer membrane was replaced every 12 hours. The decomposition of the porous silica particles was carried out by horizontal stirring at 60 rpm at 37°C. The absorbance was then measured by UV-vis spectroscopy and analyzed at λ=640 nm.

[0252] (1) Measurement of absorbance ratio The absorbance ratio of the porous silica particles of Example 2-1-(1) of the experimental method was measured according to the above method, and the results are shown in FIG. With reference to this, it was confirmed that the time t at which the absorbance ratio reached 1 / 2 was approximately 58 hours, and that the compound was decomposed very slowly.

[0253] (2) By particle size The absorbance of the porous silica particles of Experimental Example 2-1-(1), (5), and (6) was measured using the above-mentioned Equation 1. The results are shown in Figure 10 (SBF was used as the suspension and solvent). Referring to this, it can be seen that t decreases with increasing particle size.

[0254] (3) By average pore diameter The absorbance of the porous silica particles of Experimental Method Examples 2-1-(1) and (9), and the small pore porous silica particles of Experimental Method Example 2-1-(1) as a control, was measured using Equation 1. The results are shown in Figure 11 (SBF was used as the suspension and solvent). With reference to this, it can be seen that the porous silica particles of the examples have a much larger t than the control.

[0255] (4) By pH The absorbance of the porous silica particles of Example 2-1-(4) of the experimental method was measured at different pH levels. The absorbance was measured in SBF and in Tris at pH 2, 5, and 7.4. The results are shown in FIG. Referring to this, although there are differences in t depending on the pH, the t at which the absorbance ratio becomes 1 / 2 was 24 or more in all cases.

[0256] (5) Electrostatic Charge The absorbance of the porous silica particles of Example 2-2-(1)-1) of the experimental method was measured, and the results are shown in FIG. 13 (Tris (pH 7.4) was used as the suspension and solvent). With reference to this, the t value at which the absorbance ratio becomes 1 / 2 even for positively charged particles is 24 or more.

[0257] 2-5. Release of loaded nucleic acid molecules 10 μl of the porous silica particles loaded with Cy5-siRNA were resuspended in SBF (pH 7.4, 37° C.) and placed in a permeable membrane with a pore diameter of 20 kDa (tube in FIG. 14). The permeation tube was then immersed in 1.5 ml of SBF. siRNA release was carried out at 37°C with horizontal agitation at 60 rpm. Before 24 hours, the release medium was collected at 0.5, 1, 2, 4, 8, 12, and 24 hours, and then at 24-hour intervals, 0.5 ml of the release medium was collected for fluorescence measurement and an equal volume of SBF was added. The fluorescence intensity of Cy5-siRNA was measured at a wavelength of 670 nm (λ ex The extent of siRNA release was measured by measuring the fluorescence intensity at 647 nm (T = 647 nm). The results are shown in FIG. With reference to this, it can be confirmed that the time required for 50% release of siRNA was about 48 hours.

[0258] 3. In Vitro LEM-siTSLP Treatment Results 3-1. Confirmation of intracellular morphology in HaCaT and HeLa cells (1) Experimental method HaCaT or HeLa cells were cultured in an 8-well chamber (Lab-Tek Chamber slide system) at 2.0 × 10 3 After seeding, the cells were incubated for 24 hours. After washing the cells twice with 1xPBS, TAMRA fluorescently labeled siRNA (50 ng) was loaded onto FITC fluorescently labeled DDV (1 μg) to create an siRNA-DDV complex. The cells were then treated for 2 hours in serum-free media.

[0259] The DDV used was the porous silica particles of Example 2-2-(1)-2)-ii), and the siRNA used was siRNA#1.

[0260] After 2 hours, the cells were washed twice with 1xPBS. Then, the medium was replaced with 10% FBS-containing media, and the cells were stained for nuclei using Hoechst 33342 (Invitrogen) at different times (2, 6, 8, 12, 18, and 24 hours). The morphological changes of the cells and the intracellular distribution of siRNA and DDV were observed over time using a 60x lens of a Delta Vision Elite High Resolution Microscope (GE Healthcare Life Sciences).

[0261] (2) Experimental results We confirmed that a large amount of orange or yellow fluorescence was observed in the cells at the early stage, about 2 hours after the cells were treated with the siRNA and DDV complex. This is thought to be because the green fluorescent labeled DDV was introduced into the cells carrying the red fluorescent labeled siRNA, and the green and red fluorescence overlapped to produce the orange or yellow fluorescence.

[0262] It was confirmed that as time passed, the orange or yellow fluorescence decreased and the green fluorescence became predominant. This is thought to be because siRNA was released from DDV, so as time passed, the orange or yellow fluorescence disappeared and the green fluorescence of siRNA became predominant.

[0263] From the above results, it was confirmed that the complex of DDV and siRNA was efficiently delivered into cells, and the siRNA drug was slowly released within the cells.

[0264] 3-2. In vitro confirmation of TSLP mRNA knockdown by LEM-siTSLP To measure the target gene knockdown efficiency of LEM-siTSLP, the following experiment was performed on HaCaT (human keratinocyte cells) using LEM-siTSLP#1, LEM-siTSLP#14, and LEM-siTSLP#21 produced by the above-mentioned method.

[0265] Prior to carrying out the experiment to confirm TSLP mRNA knockdown, it was confirmed that TSLP expression was induced when HaCaT cells were treated with SLIGRL (see FIG. 18).

[0266] First, HaCaT cells were treated with the three types of LEM-siTSLP (25 pmol) and then cultured with 200 μM SLIGRL to induce TSLP expression. As a result, treatment of the cell line with LEM-siTSLP reduced the TSLP mRNA expression level, and treatment with LEM-siTSLP#1 in particular showed a significant effect on suppressing TSLP mRNA expression.

[0267] On the other hand, the control group (siTSLP#1, siTSLP#14, and siTSLP#21 only) was treated with siRNA alone and did not show any suppressive effect on TSLP mRNA expression in HaCaT cells (see Figure 19). This result indicates that, unlike the control group, LEM-siTSLP can efficiently transfect siTSLP into cells and induce knockdown of the TSLP gene.

[0268] 4. Sustained Release of siTSLP from LEM-siTSLP in Vitro Through this experiment, we confirmed that LEM-siTSLP maintained the TSLP knockdown effect for a longer period in HaCaT cells than LNP.

[0269] HaCaT cells were treated with LEM-siTSLP#1 (25 pmol) and LNP-loaded siTSLP#1 (25 pmol), and then TSLP expression was induced by SLIGRL treatment.

[0270] The DDV carrying siTSLP#1 used was the porous silica particles of Example 2-2-(1)-2)-ii).

[0271] In HaCaT cells, suppression of TSLP expression was sustained up to 96 hours after treatment with LEM-siTSLP#1 (TSLP expression levels, 72 hours: 15%, 96 hours: 22%), but the efficiency of LNP-loaded siTSLP#1 in suppressing TSLP expression was not high at either 72 or 96 hours (TSLP expression levels, 72 hours: 43%, 96 hours: 56%) (see FIG. 20). In other words, LEM-siTSLP suppresses the expression of target mRNA at a higher level and for a longer period in cells compared to LNP-loaded siTSLP.

[0272] 5. Ex-vivo analysis of LEM-siTSLP delivery and distribution changes Fluorescently labeled LEM-siTSLP, consisting of FITC-conjugated siTSLP loaded onto TAMRA-conjugated DegradaBALL, was injected into the cheek tissue of C57BL / 6 mice, and unloaded FITC-conjugated siTSLP alone was injected via subcutaneous injection, and the duration of LEM-siTSLP and siTSLP at the injection site was compared. Through this experiment, the delivery effect and distribution change of LEM-siTSLP were confirmed.

[0273] The DDV used was the porous silica particles of Example 2-2-(1)-2)-ii) The siTSLP used was siRNA#1.

[0274] Fluorescence imaging of excised and sectioned mouse cheek skin was performed 1, 2, and 4 days after injection. The fluorescence of TAMRA-DegradaBALL loaded with FITC-siTSLP showed strong emission at the injection site on day 1. Then, the fluorescence gradually decreased over time, but the fluorescence at the injection site remained strong until day 4 after injection (see Figures 21 and 23). The tendency of the fluorescence at the injection site to decrease over time was in line with the tendency of the skin section slides. In contrast, no fluorescent signal was observed in the excised or sectioned skin slides from mice injected with only unloaded FITC-siTSLP. This suggests that when only siTSLP without DDV was administered, siTSLP was rapidly dispersed in the body or degraded into small fragments that induce very rapid diffusion (see Figures 22 and 23). These data indicate that LEM-siTSLP treatment resulted in significantly higher levels of siTSLP in the skin, which were maintained for at least four days after injection, compared with treatment with siTSLP not loaded onto DDV.

[0275] 6. In Vivo Analysis of TSLP Knockdown Effects by LEM-siTSLP Injection The effect of TSLP knockdown in mice injected with LEM-siTSLP was confirmed by mouse behavioral analysis.

[0276] After thoroughly removing hair from the cheek tissue of the mice, PBS and DDV carrying siTSLP (0.7 nmol siRNA, 150 μg BALL in 20 μL PBS) were injected intradermally (ID) into the right cheek.

[0277] The DDV used was the porous silica particles of Example 2-2-(1)-2)-ii).The siTSLP used was one to which a sense RNA sequence (5'-CGAGCAAAUCGAGGACUGUdTdT-3' (SEQ ID NO: 124)) and an antisense RNA sequence (5'-ACAGUCCUCGAUUUGCUCGdTdT-3' (SEQ ID NO: 125)) were linked.

[0278] After 48 hours, 100 μg of SLIGRL peptide (in 20 μl PBS) was injected intradermally (ID injection) to induce TSLP. Scratching behavior was observed for 30 minutes immediately after injection, and the behavioral patterns were compared.

[0279] Specifically, we analyzed the number of times the mouse rubbed its cheek, but only counted the number of times it rubbed its cheek with its "hind paw" to distinguish it from grooming behavior. Basically, lifting and lowering a hind paw is counted as one occurrence, but if the mouse rubbed continuously for more than one second without lowering the paw, the duration was measured and counted as one occurrence per second.

[0280] FIG. 24 shows the total number of scrapes measured over a 30 minute period, and FIG. 25 shows the number of scrapes measured at 5 minute intervals.

Claims

1. a porous silica particle carrying a nucleic acid molecule within its pores that binds complementarily to at least a portion of the TSLP mRNA; The porous silica particles have an absorbance ratio of 1 / 2, as shown in the following Equation 1, of 24 or more before the nucleic acid molecule is supported on the porous silica particles: Before the nucleic acid molecules are loaded onto the porous silica particles, the porous silica particles have an average diameter of 150 nm to 1,000 nm, a BET surface area of ​​200 m 2 / g to 700 m 2 / g, and a pore volume of 0.7 ml to 2.2 ml per gram; A pharmaceutical composition for preventing or treating an atopic disease, wherein the porous silica particles are positively charged at a neutral pH inside the pores before the nucleic acid molecules are loaded thereon. [Formula 1] A t / A 0 (In the formula, A 0 is the absorbance of the porous silica particles measured by putting 5 ml of a suspension of 1 mg / ml of the porous silica particles into a cylindrical permeable membrane having pores with a diameter of 50 kDa, Outside the permeable membrane, 15 ml of the same solvent as the suspension is placed in contact with the permeable membrane, and the inside and outside of the permeable membrane are horizontally stirred at 60 rpm at 37° C., The pH of the suspension is 7.4; A t is the above A 0 is the absorbance of the porous silica particles measured after t hours have elapsed from the measurement of

2. The pharmaceutical composition for preventing or treating an atopic disease according to claim 1 , wherein the nucleic acid molecule is any one of siRNA, dsRNA, PNA, and miRNA.

3. The nucleic acid molecule is an siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 1 and an antisense RNA having the sequence of SEQ ID NO: 47, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 24 and a strand complementary thereto, an siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 2 and an antisense RNA having the sequence of SEQ ID NO: 48, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 25 and a strand complementary thereto, an siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 3 and an antisense RNA having the sequence of SEQ ID NO: 49, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 26 and a strand complementary thereto, an siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 4 and an antisense RNA having the sequence of SEQ ID NO: 50, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 27 and a strand complementary thereto, an siRNA consisting of a sense RNA having the sequence of SEQ ID NO: 5 and an antisense RNA having the sequence of SEQ ID NO: 51, a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 28 and a strand complementary thereto, an antisense RNA consisting of a sense RNA having the sequence of SEQ ID NO: 6 and a strand complementary thereto, siRNA consisting of NA, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:29 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:7 and an antisense RNA consisting of the sequence of SEQ ID NO:53, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:30 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:8 and an antisense RNA consisting of the sequence of SEQ ID NO:54, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:31 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:9 and an antisense RNA consisting of the sequence of SEQ ID NO:55, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:32 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:10 and an antisense RNA consisting of the sequence of SEQ ID NO:56, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:33 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO:11 and an antisense RNA consisting of the sequence of SEQ ID NO:57, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO:34 and a strand complementary thereto,siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 12 and an antisense RNA consisting of the sequence of SEQ ID NO: 58; dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 35 and a strand complementary thereto; siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 13 and an antisense RNA consisting of the sequence of SEQ ID NO: 59; dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 36 and a strand complementary thereto; siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 14 and an antisense RNA consisting of the sequence of SEQ ID NO: 60; dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 37 and a strand complementary thereto; siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 15 and an antisense RNA consisting of the sequence of SEQ ID NO: 61; dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 38 and a strand complementary thereto; siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 16 and an antisense RNA consisting of the sequence of SEQ ID NO: 62; dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 39 and a strand complementary thereto; sense RNA consisting of the sequence of SEQ ID NO: 17 and an antisense RNA consisting of the sequence of SEQ ID NO: 63 siRNA consisting of a strand consisting of the sequence of SEQ ID NO: 40 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 18 and an antisense RNA consisting of the sequence of SEQ ID NO: 64, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 41 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 19 and an antisense RNA consisting of the sequence of SEQ ID NO: 65, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 42 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 20 and an antisense RNA consisting of the sequence of SEQ ID NO: 66, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 43 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 21 and an antisense RNA consisting of the sequence of SEQ ID NO: 67, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 44 and a strand complementary thereto, siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 22 and an antisense RNA consisting of the sequence of SEQ ID NO: 68, dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 45 and a strand complementary thereto,The pharmaceutical composition for preventing or treating an atopic disease according to claim 2, comprising at least one siRNA or dsRNA selected from the group consisting of: siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 23 and an antisense RNA consisting of the sequence of SEQ ID NO: 69; and dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 46 and a strand complementary thereto.

4. The pharmaceutical composition for preventing or treating an atopic disease according to claim 3, further comprising a UU sequence at the 3' end of the sense RNA and the antisense RNA sequence.

5. The pharmaceutical composition for preventing or treating an atopic disease according to claim 3, further comprising a dTdT sequence at the 3' end of the sense RNA and the antisense RNA sequence.

6. The pharmaceutical composition for preventing or treating an atopic disease according to claim 3, wherein the nucleic acid molecule comprises at least one siRNA or dsRNA selected from the group consisting of: siRNA consisting of sense RNA of SEQ ID NO: 1 and antisense RNA consisting of SEQ ID NO: 47; dsRNA consisting of a strand consisting of SEQ ID NO: 24 and a strand complementary thereto; siRNA consisting of sense RNA of SEQ ID NO: 14 and antisense RNA consisting of SEQ ID NO: 60; dsRNA consisting of a strand consisting of SEQ ID NO: 37 and a strand complementary thereto; siRNA consisting of sense RNA of SEQ ID NO: 21 and antisense RNA consisting of SEQ ID NO: 67; and dsRNA consisting of a strand consisting of SEQ ID NO: 44 and a strand complementary thereto.

7. The pharmaceutical composition for preventing or treating an atopic disease according to claim 6, wherein the nucleic acid molecule comprises an siRNA consisting of a sense RNA consisting of the sequence of SEQ ID NO: 1 and an antisense RNA consisting of the sequence of SEQ ID NO: 47, or a dsRNA consisting of a strand consisting of the sequence of SEQ ID NO: 24 and a strand complementary thereto.

8. The pharmaceutical composition for preventing or treating an atopic disease according to claim 1 , wherein the porous silica particles have hydrophilic or hydrophobic functional groups.

9. 2. The pharmaceutical composition for preventing or treating an atopic disease according to claim 1, wherein the atopic disease is at least one selected from the group consisting of bronchial asthma, allergic rhinitis, urticaria, atopic dermatitis, allergic conjunctivitis, allergic dermatitis, allergic contact dermatitis, inflammatory skin diseases, pruritus and food allergies.

Citation Information

Patent Citations

  • Controlled release delivery system for bioactive agents

    JP2008512151A

  • controlled release of biological substances

    JP2008538217A

  • Composite silica particle

    JP2011121813A

  • Compositions of asymmetric interfering RNA and uses thereof

    JP2017127333A

  • Oligonucleotides down-regulating the expression of TSLP and the composites for cosmetic or pharmaceutical

    KR1020160016475A